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ABSTRACT 
    The energy required in a eukaryotic cell is provided by mitochondria. Mitochondrial 
electron transport chain (ETC) coupled with oxidative phosphorylation generates ATP. 
During electron transport, electron leakage from the ETC produces reactive oxygen 
species (ROS). In healthy cells, there are preventive and defense mechanisms in place to 
manage ROS. Maintaining a steady balance of ROS is very important because 
overproduction of ROS can lead to several pathological conditions. There are several 
strategies to prevent ROS production. Addition of external antioxidants is widely used 
among them. Discussed in the first part of Chapter 1 is the mitochondrial ETC, ROS 
production and antioxidant strategies.      
    The second part of Chapter 1 is concerned with ribosomal protein synthesis in bacteria. 
Ribosome, the organelle that synthesizes proteins with exceptional fidelity, has a strong 
bias for α-L-amino acids. It has been demonstrated that reengineering of the 
peptidyltransferase center (PTC) of the ribosome could enable the incorporation of both 
α-D-amino acids and β-amino acids into full length protein.  
    Oxidative stress is a common cause of various neurological disorders such as 
Alzheimer’s disease and Parkinson’s disease. Antioxidative strategies are used widely for 
the treatment of these disorders. Although several antioxidants demonstrated positive 
results in vitro as well as in in vivo models, none of them have been effective in clinical 
settings. Hence, there is an ongoing search for effective neuroprotective drugs. Described 
in Chapter 2 is the synthesis and biological evaluation of several methylene blue 
analogues as potentially effective antioxidants for the treatment of pathologies related to 
oxidative stress. 
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    In Chapter 3, the synthesis and ribosomal incorporation of several rationally designed 
dipeptidomimetic analogues are discussed. The dipeptidomimetic analogues are 
structurally similar to the GFP chromophore and, therefore, highly fluorescent. In 
addition, the backbone of the dipeptidomimetic analogues resemble the peptide backbone 
of a dipeptide, due to which they can be incorporated into protein by modified ribosomes 
selected for the incorporation of dipeptides.  
    Discussed in Chapter 4 is the synthesis of the pdCpA derivatives of several β-amino 
acids. The pdCpA derivatives were ligated to tRNA-COH and were used as probes for 
studying the regio- and stereoselectivity of modified ribosomes.   
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CHAPTER 1  
1.1 MITOCHONDRIAL ELECTRON TRANSPORT CHAIN: GENERAL 
INTRODUCTION        Mitochondria are the powerhouses of all eukaryotic cells. They produce energy through 
oxidative phosphorylation (OX-PHOS) in the form of adenosine triphosphate (ATP).1-4 
ATP provides the energy for many cellular processes. Apart from energy production 
mitochondria are also involved in several cellular processes such as pyrimidine5 and lipid 
biosynthesis,6 apoptosis,7 calcium homeostasis8 and flux. Therefore, damage to 
mitochondria must have widespread consequences. 
    The mitochondrial respiratory chain consists of a series of protein complexes, which 
are embedded in the mitochondrial inner membrane. Electrons provided from donor 
molecules are transferred through these complexes. This process is accompanied by the 
pumping of several protons into the intermembrane space. The potential gradient 
generated by the pumping of protons is used by ATP synthase to synthesize ATP from 
ADP and inorganic phosphate.9,10 The complexes in the mitochondrial inner membrane 
are NADH dehydrogenase (complex I), succinate dehydrogenase (complex II), 
cytochrome bc1 (complex III), cytochrome c oxidase (complex IV) and ATP synthase 
(complex V). All of these complexes contain Fe_S prosthetic groups. Additionally, 
complexes I and II have flavin mononucleotide (FMN) and flavin adenine dinucleotide 
(FAD), respectively, whereas complexes III and IV have heme groups. Two mobile 
carriers, namely ubiquinone and cytochrome c, are also part of the ETC. Electron 
transport begins with the transfer of two electrons from NADH to complex I; coupled 
with this is the transfer of four protons to the intermembrane space. These two electrons 
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are then transferred to ubiquinone, which transfers them to complex III. Similarly, 
succinate donates two electrons to complex II. These are also carried to complex III by 
ubiquinone. Electron transport through complex III results in the transfer of two protons 
to the intermembrane space. Cytochrome c acts as the mobile carrier between complexes 
III and IV. Complex IV accepts electrons, one at a time and one proton is pumped into 
the intermembrane space for each electron. In complex IV, four electrons, O2 and four 
protons interact to form two water molecules; the other four protons are pumped across 
the membrane into the intermembrane space. The ten protons transported to the 
intermembrane space generate a proton electrochemical gradient; this gradient is utilized 
by ATP synthase to synthesize ATP from ADP and inorganic phosphate.11,12 The electron 
transport chain is illustrated in the following figure13: 
e inner
 mitochondrial
membrane
outer
 mitochondrial
membrane
intermembrane
 space
e
I
II e
III IV
e
Q
Cyt
 c
O2
H2O
ADP
 + Pi ATP
4H+ 4H+2H+
V
NADH NAD+
O2 O2
FADH2 FAD
H+
mitochondrial
 matrix
 
Figure 1.1. Electron transport chain in mitochondria.   
    Mitochondria consume the most oxygen of all the organelles in a cell in order to 
maintain the production of a large amount of ATP. ATP synthase utilizes the gradient 
generated by the passage of about three protons to generate one ATP. Thus, one NADH 
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and one succinate produce ~ 3ATPs and ~ 2ATPs, respectively. Eighty percent of oxygen 
consumption related to ATP production occurs in mitochondria.14 During electron 
transport leakage of a small portion of electrons, mostly at complexes I and III, leads to 
the formation of superoxide anion (O2.-) which is then converted to other reactive oxygen 
species (ROS). These are very reactive and can damage cellular components including 
proteins, lipids and nucleic acids. The overproduction of ROS is believed to be the key 
cause of aging and many neuropathological diseases.15 
    ROS is a term used to describe molecular oxygen derived chemical species with 
unpaired electrons. ROS include hydroxyl radical (.OH), superoxide anion (O2.-), singlet 
oxygen and peroxynitrite (ONOO-).16 The reduction potential of the O2/O2.-  pair is about 
_0.15 V which means that the oxidation of cellular compounds by molecular oxygen is a 
thermodynamically favorable process. Normally, it doesn’t occur because the process is 
kinetically unfavorable due to high activation energy.16 However, for highly reactive 
respiratory chain electron carriers such as reduced flavins, non-heme iron proteins, 
quinols and especially semiquinones, the activation energy for electron transfer is low. 
Therefore, instead of the desired four electron reduction of oxygen by complex IV, O2.- is 
formed by a one-electron reduction. Superoxide radical (O2.-) disproportionates (either 
spontaneously or by the action of superoxide dismutases) to H2O2. Hydrogen peroxide 
can generate hydroxyl radicals (.OH) in presence of lower valent transition metals like 
copper or iron by the Fenton reaction (Figure 1.2).17 Hydroxyl radical is an extremely 
strong oxidant, which can oxidize practically everything. 
H2O2 + Fe2+ Fe
3+ + .OH + -OH  
Figure 1.2. Formation of hydroxyl radicals by the Fenton reaction. 
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    To prevent the deleterious effects resulting from the formation of ROS, there are 
several natural defense mechanisms in cells. This is illustrated in Table 1.1.18 In general, 
Table 1.1. Different types of defense mechanisms against ROS. 
  
 Actions Example 
Prevention 
Protein binding of 
metal ions like 
copper and iron 
Transferrin, ferritin, 
albumin 
Enzymatic 
neutralization 
Conversion of ROS 
to nontoxic 
products 
Superoxide dismutase, 
catalase, glutathione 
peroxidase 
Scavenging 
Sacrificial 
interaction with 
ROS by 
expendable 
(replaceable or 
recyclable) 
substrates 
Ascorbic acid, α-
tocopherol 
Quenching Absorption of electrons 
α-Tocopherol, β-
carotene 
 
any species that can prevent oxidation is an antioxidant. Antioxidants can be divided into 
two classes, enzymatic and non-enzymatic antioxidants.19 Glutathione peroxidase, 
catalase and superoxide dismutase are among the enzymatic antioxidants. Superoxide 
dismutase (SOD) destroys the free radical superoxide by converting it into peroxide that 
can be destroyed by catalase or glutathione peroxidase (GPX) (Figure 1.3).19 
H2O2 + 2GSH
GPX
GSSG + 2H2O
O2 + O2 + 2H+
SOD H2O2 + O2  
Figure 1.3. Quenching of ROS by superoxide dismutase and glutathione peroxidase.  
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Non-enzymatic antioxidants include α-tocopherol or vitamin E, L-ascorbic acid, 
glutathione (GSH), β-carotene, resveratrol, curcumin (non-flavonoids) and quercetin 
(flavonoid) (Figure 1.4 and 1.5).18,20-23 
O
HO
CH3 CH3
α-tocopherol (vitamin E)
O OHO
HO H
HO OH
L-ascorbic acid (vitamin C)
HO N
H
H
N
OH
O
O
OO
NH2
SH
glutathione (GSH)  
Figure 1.4. Chemical structures of vitamin E, vitamin C and glutathione.  
O
O
OH
OH
HO
OH
OH
quercetin
OH
OH
HO
resveratrol
O O
H3CO
OH
OCH3
OH
curcumin  
Figure 1.5. Chemical structures of quercetin, resveratrol and curcumin.  
Vitamin E is a chain breaking antioxidant because it interferes with one or more of the 
propagation steps of lipid peroxidation. Vitamin E is the collective term for a family of 
structurally related chemical substances. It naturally occurs in eight different forms: α, β, 
γ, d-tocopherols and α, β, γ, d-tocotrienols (Figure 1.6).24,25  
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O
HO
R2
R1
R3
CH3 CH3
O
HO
R2
R1
R3
CH3 CH3
Compound                   R1             R2              R3
α-tocopherol                 CH3           CH3           CH3 
β-tocopherol                 CH3               H              CH3  
γ-tocopherol                  H              CH3           CH3
d-tocopherol                  H               H              CH3
Compound                   R1             R2              R3
α-tocotrienol                 CH3           CH3           CH3 
β-tocotrienol                 CH3                H             CH3  
γ-tocotrienol                   H             CH3           CH3
d-tocotrienol                   H              H              CH3  
Figure 1.6. Chemical structures of members of the vitamin E family.  
    ‘Oxidative stress’ is an expression used to describe various deleterious processes 
resulting from the formation of excessive ROS. The steady state concentrations of O2.- 
and H2O2  in normal mitochondria are ~10-10 M and 5 x 10-9 M, respectively.16 During 
intracellular signaling small fluctuations in the steady-state concentrations of ROS are 
observed but a several-fold increase in the steady-state concentrations of these oxidants 
can lead to indiscriminate chain reactions with proteins, lipids, DNA and 
polysaccharides. The peroxidation of lipid membranes by hydroxyl radicals is well 
documented.26,27 A carbon centered radical (R.) is formed due to the abstraction of 
hydrogen from the lipids. This is the chain initiation reaction. The radical R. reacts 
extremely rapidly with oxygen to form the peroxyl radical (ROO.). The peroxyl radical 
can abstract a hydrogen atom from another lipid molecule, forming another carbon 
centered radical (R.). Thus a single hydroxyl radical is capable of forming many lesions, 
which ultimately breach the integrity of lipid membranes (Figure 1.7). 
RH   +   OH R + H2O
R   +   O2
ROO  +  RH ROOH   +   R
Initiation
PropagationROO  
Figure 1.7. Free radical chain reaction and lipid peroxidation.  
    As discussed before, CoQ10 is the carrier molecule, which transfers electrons from 
complexes I and II to complex III. In the reduced form, it is one of the most potent 
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antioxidants present in mitochondria, capable of quenching lipid peroxidation.27 α-
Tocopherol, one of the members of the vitamin E family, is a phenolic compound and is 
also very effective in quenching lipid peroxidation.26 Phenolic antioxidants can suppress 
lipid peroxidation in two ways, by quenching the carbon centered radical during initiation 
step (preventive antioxidants) or by quenching the peroxyl radical during chain 
propagation step (chain-breaking antioxidants).26 It has been demonstrated that phenolic 
antioxidants are chain-breaking antioxidants because they quench peroxyl radicals much 
faster than carbon centered lipid radicals.  
    When α-TOH quenches a peroxyl radical, α-TOH itself is converted to a radical (α-
TO.). Due to effective resonance stabilization (Figure 1.8) α-TO. is much less reactive and 
does not react with carbon centered lipid radicals.28-31 α-TO. is recycled back to α-TOH 
by cellular ascorbic acid and NADH. 
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O
OH
R
ROOH
O
O
R O
O
R
ascorbic acid ascorbic acid
NADH NAD+
ROO
 
Figure 1.8. Quenching of lipid peroxidation by α-tocopherol and recycling of α-
tocopherol by ascorbic acid and NADH. 
 
    Mitochondria are rapidly emerging as major contributors to human health and disease. 
Hence, the appropriate operation of mitochondria is extremely important. Scientists are 
always in search of new lead compounds for the treatment of mitochondrial diseases. 
Many compounds, which are effective in vitro, do not show the anticipated efficacy in 
vivo. In this thesis, the synthesis and biological evaluation of several methylene blue 
analogues as antioxidants has been described. Preliminary studies indicate that some of 
the analogues are better antioxidants compared to methylene blue itself.  
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1.2 RIBOSOMAL PROTEIN SYNTHESIS: GENERAL INTRODUCTION  
    The ribosome is a large ribonucleoprotein particle that directs the synthesis of proteins. 
The bacterial ribosome consists of a large (50S) subunit and a small (30S) subunit; 
together these two subunits form the 2.5 megadalton 70S ribosome. The 50S subunit 
consists of 23S rRNA, 5S rRNA and about 30 proteins whereas the 30S subunit is made 
of 16S rRNA and about 20 proteins.32,33 The ribosome synthesizes proteins using 
messenger RNA (mRNA) and transfer RNA (tRNA) with the help of several protein 
factors. The large subunit contains the peptidyltransferase center, which is responsible for 
forming peptide bonds; whereas the small subunit contains the codon recognition center 
in which charged tRNA decodes the codon sequence of mRNA. Each ribosomal subunit 
has three sites for tRNA binding, namely the A-site or acceptor site for aminoacyl-tRNA, 
the P-site or peptidyl site that binds peptidyl-tRNA containing the nascent polypeptide 
chain and the E-site or exit site from which deacylated tRNA exits the ribosome (Figure 
1.9).33 Bacterial protein synthesis can be divided into three steps- initiation, elongation 
and termination. Bacterial protein synthesis always starts by positioning 
formylmethionyl-tRNAfMet over the start codon (AUG) on the P-site. Therefore, 
ribosomally translated bacterial proteins always contain formyl-methionine at the 
beginning, which are processed by posttranslational modifications later. In bacteria, the 
30S ribosomal subunit is positioned in the vicinity of the mRNA start codon, and the 3′-
end of the 16S ribosomal RNA base pairs with its complementary Shine–Dalgarno 
sequence in the bound mRNA.32 Three initiation factors (IF1, IF2 and IF3) are also 
involved in the formation of this 30S initiation complex (30S-IC). The 30S-IC then 
recruits the 50S subunit to form an intact 70S ribosome, all set to start protein synthesis.  
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    Protein elongation occurs due to the nucleophilic attack by the α-amino moiety of the 
aminoacyl-tRNA in the A-site, on the carbonyl carbon of the amino acid bound to the 
tRNA in the P-site (Scheme 1.1a). As a result, the nascent peptide is transferred onto the 
tRNA occupying the A-site, adding a new amino acid to the growing chain while the 
tRNA occupying the P-site is deacylated (Scheme 1.1b). This event is driven by the 
hydrolysis of GTP followed by translocation of the mRNA and ribosome relative to one  
 
Figure 1.9. Schematic diagram of the ribosome.  
another. In essence, the ribosome shifts three nucleotides (one codon) along the mRNA in 
the 5′ to 3′ direction. This is accompanied by the movement of the peptidyl-tRNA in the 
A-site to the P-site and the deacylated tRNA in the P-site to the E-site of the ribosome 
(Scheme 1.1c). Following this event a new cycle begins in which another aminoacyl-
tRNA binds to the A-site and the deacylated tRNA dissociates from the E-site (Scheme 
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1.1d).32 Each amino acid is added to the nascent peptide chain accompanied by the 
hydrolysis of at least two GTP molecules. One GTP molecule is hydrolyzed during 
aminoacyl-tRNA selection as a ternary complex and another is hydrolyzed during 
translocation. Each elongation cycle takes about one-twentieth of a second.34 
Scheme 1.1. Peptide bond formation in PTC. 
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The ribosome increases the rate of peptide bond formation by at least 105-fold. It has 
been shown that the catalytic site is in domain 5 of 23S rRNA. Since RNA is responsible 
for the catalytic activity, the ribosome is also a ribozyme.35 
    Among the 64 trinucleotide codons, there are three codons, which do not encode any 
amino acid; their function is to terminate translation. These three codons are designated 
stop codons, namely UAA, UAG and UGA. There are generally no tRNAs whose 
anticodons are complementary to the stop codons.    Hence, when the ribosome detects 
one of these stop codons, elongation is stopped and the polypeptide is released; this is 
known as translation termination. Termination requires the presence of one of the three 
release factors, which recognize the stop codons and cleave the polypeptide chain from 
the P-site tRNA. There are three release factors in bacteria: release factor 1 (RF1), which 
recognizes UAA and UAG stop codons; release factor 2 (RF2), which recognizes UAA 
and UGA stop codons; release factor 3 (RF3), which is not codon specific but increases 
the activity of other factors.32,34 Studies show the similarity between the structures of the 
release factors and tRNA, due to which the release factors can enter the A-site of the 
ribosome.   
   During protein synthesis, the overall translation error rate ranges from 6 x 10-4 to 5 x 
10-3 which is the result of net error accumulation from several steps, including 
transcription (10-4), aminoacyl-tRNA synthesis (10-4), and ribosomal decoding (10-4).36-39 
There are two steps involved in the aminoacylation by aminoacyl-tRNA synthetases; first 
the formation of an aminoacyladenylate or aminoacyl-AMP and then the transfer of the 
amino acid to the cognate tRNA. Aminoacyl-tRNA synthetases often employ unique 
proofreading mechanisms to maintain translational fidelity (also known as editing).36 
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Although Linus Pauling and Francis Crick foresaw the need for an editing mechanism for 
structurally similar amino acids during protein synthesis, the actual experimental 
observation was first reported by Baldwin and Berg.40 They demonstrated that the 
addition of tRNAIle accelerated the breakdown of misactivated Valyl-AMP bound to Ile-
RS.  
    The idea that the ribosome plays a crucial role in maintaining translational fidelity was 
first demonstrated in 196441 when the production of an essential enzyme in mutant cells 
in the presence of streptomycin was reported. Without streptomycin the enzyme was not 
produced because of the presence of a stop codon in the gene encoding for the protein. 
Streptomycin resulted in misreading of the mRNA template in in vitro translation 
reactions. Thus, ribosome structural modulations by streptomycin appeared to influence 
the accuracy of protein translation.  
    Ribosome accepts aminoacyl-tRNA in the A-site as a ternary complex of aminoacyl-
tRNA with elongation factor Tu (EF-Tu) and GTP to form the initiation complex.32,42 The 
rate constant (k1, Figures 1.10, 1.11 and 1.12) for the formation of this complex is same 
for cognate, non-cognate or near-cognate ternary complexes.42 When there is codon 
recognition the complex is stabilized (k2). Codon recognition results in conformational 
change of EF-Tu towards the active conformation for GTP hydrolysis (GTPase 
activation, k3). After GTP hydrolysis (kGTP), EF-Tu changes its conformation (k4), looses 
the affinity for aminoacyl-tRNA and dissociates (k6), leaving the aminoacyl end of 
aminoacyl-tRNA to move into the peptidyltransferase center (Accomodation, k5) where it 
can take part in peptide bond formation (kpep). This is depicted in Figure 1.10.42 The 
initiation complex dissociates rapidly (slow k3, fast k-2, Figure 1.11), before GTP 
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hydrolysis, for non-cognate ternary complexes. This is known as initial selection. Thus, 
the bulk of the non-cognate ternary complexes are discarded without GTP hydrolysis. 
This is depicted in Figure 1.11.42  
 
Figure 1.10. Kinetic mechanism displaying the binding of aminoacyl-tRNA to the 
ribosomal A-site. Numbered rate constants indicate kinetically resolved steps. kGTP, kPi, 
kpep indicate steps which are rate-limited by the preceding steps. P and A designate the P-
site and A-site of ribosome. Elongation factor Tu (EF-Tu) is shown differently in the 
GTP and GDP bound state. GTP* indicates GTP-ase activity (reference 41). 
 
    The screening of near-cognate ternary complexes is more complex. Upon initial 
selection near-cognate ternary complex is stabilized (fast k2, slow k-2, Figure 1.1242), 
stimulating the hydrolysis of GTP in EF-Tu (GTPase activation, k3). Although both the 
values of k-2 and k3 are several fold lower for near-cognate case compared to cognate 
case, rapid and irreversible GTP hydrolysis drives the equilibrium forward for near-
cognate case. For the majority of near-cognate aminoacyl-tRNA, discrimination takes 
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place in the subsequent proofreading step because of the less stable codon-anticodon 
interaction than cognate one (fast k7). 
 
Figure 1.11. Kinetic mechanism showing discrimination against non-cognate ternary 
complexes. Black-rate constants do not contribute to the discrimination because they are 
the same for cognate and non-cognate ternary complexes. Rate constants in red are 
specific for cognate ternary complexes and green are for non-cognate ternary complexes 
(reference 41). 
 
    Ribosomal protein synthesis is limited to α-L-amino acids.43 The ribosomal 
peptidyltransferase center can differentiate between individual amino acids and is 
sensitive to the structure as well as chirality of the amino acids. For example, initial 
efforts to incorporate α-D-amino acids were largely unsuccessful.44-46 There have been 
numerous efforts to incorporate nonnatural amino acids into preselected positions of 
proteins. The major strategy for the site-specific incorporation of nonnatural amino acids 
into proteins was by the suppression of stop codons (UAG) using chemically misacylated 
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Figure 1.12. Kinetic mechanism for the discrimination against near-cognate ternary 
complexes. Black rate contants are same for cognate and near-cognate ternary complexes. 
Rate constants in red are specific for cognate ternary complexes and those in blue are 
specific for near-cognate ternary complexes and hence contribute to discrimination 
(reference 41). 
 
suppressor tRNAs having CUA anticodons. Hecht and coworkers developed a chemical 
method to covalently attach a non-natural amino acid to the 3′-end of tRNAPhe.47,48 
Chemically misacylated pCpA was attached to an abbreviated tRNA using T4 RNA 
ligase. Schultz and coworkers used pdCpA instead pCpA to overcome the synthetic 
difficulties of preparing pCpA. The same groups then used these misacylated tRNAs for 
the site-specific incorporation of unnatural amino acids in cell-free protein synthesizing 
systems.49-51 Schultz and coworkers also developed a strategy to incorporate unnatural 
amino acids into proteins in vivo.52   
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    A lot of work has been done to change the translation property of ribosomes by 
changing the critical nucleotides in the PTC, yet until recently there had been no report of 
the incorporation of non-natural amino acids into protein by modified ribosomes. 
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Figure 1.13. Strategy for the incorporation of unnatural amino acids into proteins in 
vitro.53 
 
    Puromycin (Figure 1.14) is an aminonucleoside antibiotic, which acts as an inhibitor of 
 
protein synthesis in intact cells as well as cell free extracts of different organisms. The 
structure of puromycin resembles the 3'-end of an aminoacyl-tRNA (Figure 1.14) which 
makes it a putative aminoacyl-tRNA mimic.54 Thus ribosomal A-site recognizes 
puromycin as aminoacyl-tRNA. The free amino group of puromycin then takes part in 
peptide bond formation with the nascent polypeptide attached to the peptidyl-tRNA in the 
P-site, resulting in premature chain release.54 Puromycin, and its derivatives having 
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Figure 1.14. Structural similarity between puromycin and 3'-end of aminoacyl-tRNA.54 
different amino acid side chains show different ribosomal inhibition efficiencies.55,56 
Thus, it seemed possible that in order to mediate the incorporation of non-natural amino 
acids by ribosomes with altered peptidyltransferase centers, the modified ribosomes 
could be selected using puromycin analogues containing the amino acid structure of 
interest.  
    Modification of the peptidyltransferase center (PTC) can be a novel strategy for 
incorporation of nonnatural amino acids. Hecht and coworkers exploited this idea by 
successfully preparing modified ribosomes having modifications in two regions (2447-
2450 and 2457-2462), which correspond to the PTC and helix 89 of Escherichia coli 23S 
rRNA.57 The ribosomes were able to incorporate α-D-methionine and α-D-phenylalanine 
into E. coli dihydrofolate reductase (DHFR) in enhanced yields.57 Following this success, 
the same group reported the selection of ribosomes having modifications in the PTC of 
the 23S rRNA using β-puromycin (1.1, Figure 1.15).58,59 The modified ribosomes were 
able to incorporate five β-amino acids including β-alanine into DHFR.53,59 In all these 
cases the modified ribosomes were able to incorporate a single unnatural amino acid by 
the suppression of a single stop codon. In 2015, the modified ribosome technology was 
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extended importantly when Hecht and coworkers reported the incorporation of dipeptides 
and dipeptide mimic analogues into position 10 of DHFR by the suppression of a single 
stop codon using modified ribosomes selected against a puromycin analogue containing a 
dipeptide (1.2, Figure 1.15).60  
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Figure 1.15. Structures of puromycin derivatives.  
    In this thesis, the syntheses of several dipeptidomimetic analogues are described. The 
dipeptidomimetic analogues included analogues of the chromophore of green fluorescent 
protein (GFP) and were, therefore, highly fluorescent. Additionally, some of the 
dipeptidomimetic analogues were incorporated into position 66 of GFP and the 
photophysical properties of the proteins were determined. Also described are the 
syntheses of the pdCpA derivatives of several β-amino acids, which were used as probes 
for the study of the regio- and stereoselectivity of the selected modified ribosomes. 
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CHAPTER 2 
 
2. METHYLENE BLUE AND METHYLENE VIOLET ANALOGUES AS 
MULTIFUNCTIONAL RADICAL QUENCHERS 
2.1 Introduction 
Phenothiazine and methylene blue: a historical background 
    Phenothiazine (Figure 2.1) is arguably the most promiscuous lead structure of 20th 
century medicinal chemistry.61 Methylene blue (MB) was the first phenothiazine to be 
used as an antimalarial agent by Paul Ehlrich in the late 1880s. Phenothiazines were 
administered to humans as anthelmintic agents in the 1930s and 1940s.62 The use of 
phenothiazines expanded in the 1950s when researchers at Rhône-Poulenc Laboratories 
in France developed derivatives of phenothiazine having antihistaminergic and 
antipsychotic properties.63 Although the redox properties of phenothiazine and some 
congeners have been known for decades, their application as such was limited to the 
engineering industry. With increasing evidence of the role of oxidative stress in many 
degenerative human pathologies, there has been a steady increase in the investigation of 
phenothiazine, MB and other derivatives for the treatment of neurodegenerative diseases 
like Parkinson’s disease and Alzheimer’s disease.61  
    Methylene blue (MB) (Figure 2.1) has been used as a medicine for many years in the 
treatment of various pathological conditions.64 The therapeutic potential of MB has been 
demonstrated against many diseases including methemoglobinemia and malaria as well 
as cyanide and carbon monoxide poisoning. MB is a derivative of phenothiazine; it was 
first synthesized by Heinrich Caro at BASF in 1876 and by Bernthsen in 1883. The 
structure was later determined by Bernthsen in 1885.61 
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Figure 2.1. Chemical structures of phenothiazine and MB.  
    Ehlrich first described the redox properties of MB. While staining different tissues in 
vivo he saw variable, reversible reduction of MB to its leuco form in certain organs such 
as liver and lung. After exposure to ambient oxygen the blue color returned.61 By the end   
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ox  
Figure 2.2. Redox cycling of methylene blue.   
of the 1940s Charles Murphy et al. had demonstrated that phenothiazine could prevent 
the oxidation of turbo-jet engine lubricants even at temperatures above 100 oC.62 
Numerous derivatives of phenothiazine were synthesized and patented in 1950s and 
1960s with ongoing use to date.65 Decades later, in 1991, Yu et al. used phenothiazines as 
chemicals that potently protected cells, especially neurons, from oxidative stress.66 
Antioxidant property of phenothiazines: a comparison 
    Following the report of Yu et al. in 1991, there have been myriad studies involving the 
antioxidant properties of phenothiazine and its derivatives. But until recently, little 
information was available regarding the structure-activity relationships with respect to 
antioxidant properties between different phenothiazine derivatives. In 2012 the Yang 
group from University of North Texas Health Science Center investigated the structure-
activity relationships between several phenothiazine analogues (Table 2.1).67 The 
derivatives comprise three major modifications of phenothiazine (Figure 2.3), namely,   
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Table 2.1. EC50 values for viability, ROS of the phenothiazine analogues in the HT-22 
glutamate toxicity assay. 
        
Drug Viability (nM) ROS (nM) 
Phenothiazine 19 57 
Promethazine 1070 9700 
Methylene blue 18 20 
Toluidine blue 1.8 0.1 
Neutral red 5800 15760 
 
(i) substitution of the hydrogen at position 10 (promethazine), (ii) introduction of amine 
groups at positions 3 and 7 (methylene blue and toluidine blue) and (iii) substitution of 
sulfur with nitrogen at position 5 (neutral red). The parent compound phenothiazine was 
highly effective in a glutamate neurotoxicity assay, as well as in mitigating ROS (Table 
2.1). In the glutamate neurotoxicity assay, glutamate blocks the glutamate/cysteine 
antiporter due to saturating concentrations of extracellular glutamate, causing depletion 
of cellular glutathione and increasing ROS. The results were also similar for iodoacetic 
acid (IAA) and rotenone neurotoxicity assays. The second compound, promethazine, 
having a side chain at the 10-position was less potent in all of the assays (Table 2.1). The 
third group of compounds having amine side chains at the 3 and 7 positions (MB and TB) 
were the most potent in all of the assays. The fourth group consisted of the compound 
neutral red (NR). NR is the phenazine analogue of TB. It showed minimum potency in 
the neuroprotective assays. In conclusion, the structure-activity relationship study 
indicated the importance of having hydrogen at the 10-position as well as having sulfur at 
position 5. Although phenothiazine had similar potency compared to MB and TB in the 
neurotoxicity assays, MB and TB are better drug candidates because they have the unique 
capability of acting as electron shunts between complexes I and III.67  
 23   
S
N
phenothiazine
S
N
N
promethazine
S
N
NN Cl
methylene blue (MB)
S
N
NH2N Cl
toluidine blue (TB)
N
N
NH2N
neutral red (NR)
1
2
3
4
9
8
7
6 5
10
H
 
Figure 2.3. Chemical structures of the phenothiazine analogues compared for antioxidant 
properties. 
 
Distinct neuroprotective action of MB 
    Mitochondrial dysfunction is a pathological condition that is a common feature of 
many neuropathological disorders including Alzheimer’s disease, Parkinson’s disease 
and stroke. Several antioxidants have been studied extensively for the treatment of 
neurological disorders. For example, CoQ10 has been used as an endogenous electron 
transport chain (ETC) supplement to treat Parkinson’s disease, singly or in combination 
with other antioxidants such as creatine. Estrogen has been found to increase gene 
expression for many key components of the ETC. However, none of these treatments 
proved successful in clinical studies, casting doubt on such neuroprotective strategies.                     
Inhibition of mitochondrial complex IV with KCN and complex V with oligomycin 
demonstrated that inhibition reduced cell growth but did not result in cytotoxicity or cell 
death. On the contrary, inhibition of complex I with rotenone or complex III with 
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antimycin caused direct cytotoxicity and cell death. This is presumably because inhibition 
of complex I/III caused leakage of electron, which in turn increased ROS and induced 
cytotoxicity. Since complexes IV and V are not involved in electron leakage and ROS 
production, cells survive by anaerobic glycolysis and lactate production. Therefore, 
bypassing complex I/III can be an alternative neuroprotective strategy. Studies show that 
MB mediated electron transfer is insensitive to complex I/III inhibition, indicating an 
alternate route of electron transfer.68 Due to the low reduction potential (11 mV), MB can 
easily cycle between oxidized and reduced forms.69 Upon completion of a cycle, 
electrons from NADH are delivered to cytochrome c bypassing the inhibition of 
complexes I and III. 
MB in photodynamic therapy (PDT) 
    Phenothiazinium dyes acting as photosensitizers in PDT treatment of various cancers, 
and in antimicrobial research have been studied extensively.70,71 In PDT, a combination 
of photosensitizing agent and light causes the formation of singlet oxygen (ROS), which 
is responsible for tumor death, either by necrosis or apoptosis. Photodynamic 
antimicrobial chemotherapy (PACT) is also based on the same principle. For decades it 
has been known that phenothiazinium dyes like MB can stain microbes. It is therefore 
possible to kill the microbes by illumination. PACT can be used for the disinfection of 
blood samples before blood transfusion.72-75 
    MB is a primary candidate in the PDT therapy of several cancers. In aqueous solution 
it produces an intense blue color. Due to its extended conjugation system, the energy 
difference between the electronic states of MB is reduced such that it strongly absorbs 
visible light in the region 600-700 nm, thus allowing the rest of the visible spectrum to be 
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transmitted (350-600 nm). MB acts as an effective photosensitizer because it can pass on 
the absorbed light energy to nearby molecules.  
    There have been extensive structure-activity studies related to the photodynamic action 
of phenothiazinium dyes.76-79 The photodynamic action of a photosensitizer is largely 
dependent on the lipophilicity (relative solubility in lipids and water, log P) of the 
molecules. MB is an effective phototoxic agent against a variety of tumor cell lines in 
vitro.79,80 MB demonstrated effective photodynamic activity in vivo, when administered 
directly into the tumor. When solid Ehrlich carcinomas were treated with intratumoral 
MB followed by illumination with red light, significant tumor reduction and destruction 
was observed.81 Nonetheless, there has been only limited success in clinical study of 
MB,82,83 especially when injected intravenously or intravesically, which might be a result 
of poor localization of MB in tumors due to its high hydrophilicity. MB has a log P value 
of _1.0,76 which means when partitioned between water and octanol, MB will be mostly 
in the aqueous phase. 
    In order to draw a correlation between photodynamic activity and lipophilicity, Mellish 
et al. synthesized several MB analogues with varying alkyl chains on the exocyclic 
amines (Figure 2.4).76 The log P values followed the order 
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Figure 2.4. Chemical structures of lipophilic MB analogues.  
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n-pentyl > n-hexyl > n-butyl > n-propyl > ethyl > methyl. In vitro phototoxicity toward 
RIF 1 fibrosarcoma cells followed the order n-propyl > n-pentyl > n-butyl > n-hexyl > 
ethyl > methyl. As expected, in vitro phototoxicity on the lipophilic MB analogues were 
better compared to MB itself due to improved cellular uptake, although the order was 
somewhat ambiguous.76 
Designing the target compounds 
    Due to the negative charge in the membrane of the mitochondrial matrix and high 
potential gradient through the inner membrane, lipophilic compounds with delocalized 
positive charge concentrate in much higher amounts in mitochondria than other 
organelles. Therefore, in analogy with the study of Mellish et al., the use of lipophilic 
MB analogues having long alkyl chains might be a good strategy to target mitochondria. 
However the position of the alkyl chain is crucial. N-alkylated MB analogues are 
lipophilic and relatively easy to synthesize. But MB is metabolized in vivo, yielding the 
demethylated analogues, azure A and azure B (Figure 2.6).84 These demethylated 
analogues are found in the urine of the patients treated with MB. Therefore, in principle, 
the alkyl side chains may be removed during metabolism, changing the polarity of the 
compounds. To eliminate this possibility our analogues were designed such that the long 
alkyl chains are positioned at one of the six available aromatic positions. In addition, to 
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Figure 2.5. Chemical structures of azure A and azure B.  
alter the electronic properties of the analogues, which might influence the antioxidant 
properties, the dimethylamine moieties at 3 and 7 positions were substituted with 
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different secondary amines including piperidine and morpholine. Figure 2.6 shows the 
chemical structures of the synthesized MB analogues.            
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Figure 2.6. Chemical structures of the synthesized MB analogues.  
Designing methylene violet analogues 
    The substantial hydrophilicity of MB may restrict its transport across the plasma 
membranes of some mammalian cells, which would also limit its cellular uptake. For this 
reason, we have been interested in MB analogues with increased hydrophobicity. 
Methylene violet (MV) is a neutral phenothiazine dye.85 Hydrolysis of MB under 
strongly basic condition yields MV. In addition to improved hydrophobicity, a structure-
activity relationship can be drawn between MB and MV. MV can be looked upon as a 
phenolic analogue of MB where a hydroxyl group substitutes one of the two 
dimethylamine moieties. Although MV is naturally obtained in the oxidized (quinone) 
form, it can be reduced by the mitochondrial redox centers generating the phenolic 
(quinol) form. The reduced form of MV can act as phenolic antioxidants similar to 
CoQ10. The proposed mechanism of antioxidant activity of MV is shown in Scheme 2.1. 
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Scheme 2.1. Proposed mechanism of antioxidant activity of MV analogues.  
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    In order to modulate the polarity of the molecules, alkyl side chains having varying 
numbers of carbon atoms were attached either to the exocyclic amine at position 3 or on 
the aromatic ring at position 6. Figure 2.7 shows the MV analogues synthesized having 
aliphatic substituents on the exocyclic nitrogen atom. 
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Figure 2.7. MV analogues having long chain alkyl groups on the exocyclic amine.  
    Figure 2.8 illustrates the MV analogues carrying long chain alkyl groups on the 
aromatic ring. In addition, the dimethylamine moiety was also substituted with piperidine 
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and morpholine (2.12 and 2.13) to explore the effect on the antioxidant properties of the 
molecules.  
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Figure 2.8. MV analogues having long chain alkyl substituents on the aromatic ring.  
2.2 Results  
Synthesis of the MB and MV analogues 
    The synthesis of the lipophilic MB analogues started with the protection of the                                                                                  
hydrogen at position 10 of commercially available 2-cyanophenothiazine. Treatment of 
2-cyanophenothiazine with 60% NaH at 0 oC yielded the corresponding anion which was 
subsequently treated with di-tert-butyl dicarbonate to obtain 2.14 in quantitative yield. 
Reductive hydrolysis of 2.14 by DIBAL-H and ~2 N HCl afforded 2.15 in 58% yield.86 
Compound 2.15 was subjected to the Wittig reaction with 
hexadecyltriphenylphosphonium bromide in the presence of 1 M NaHMDS to afford an 
intermediate alkene as a cis-trans mixture; this was subsequently reduced by 
hydrogenolysis using palladium-on-carbon as catalyst to obtain the corresponding alkane 
2.16 in 74% yield over two steps. In the next step, the Boc protecting group was removed 
using 10 equivalents of trifluoroacetic acid to obtain 2.17. Oxidation of 2.17 with iodine 
in CH2Cl2 followed by the subsequent addition of different secondary amines afforded 
2.1-2.4 in varying yields (Scheme 2.2-2.4).87 
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Scheme 2.2. Synthesis of 2.1 and 2.2.  
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Scheme 2.3. Synthesis of 2.3. 
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Scheme 2.4. Synthesis of 2.4.  
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   MV analogues 2.11-2.13 were obtained by the basic hydrolysis of 2.1, 2.3 and 2.4, 
respectively (Scheme 2.5). 
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Scheme 2.5. Synthesis of 2.11-2.13.  
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    The synthesis of the MV analogues having long alkyl substituents on exocyclic 
nitrogen atoms was carried out using the Smiles rearrangement88 as one of the key steps. 
The retrosynthetic analysis is shown in Scheme 2.6. 
Scheme 2.6. Retrosynthetic analysis for MV analogues having long alkyl substituents on 
the exocyclic amine. 
S
N
ON
R
R
S
N
H2N O
P
P
S
H
N
O2N O
P
S
NH2 NO2 NO2
O
P
O
NH2
SH
P
O S
N
NH2
Cl
NO2
NO2
+
Commercially available Commercially
   available
P = protecting group
1
2
3
4
5
6
7
8 9
10
 
    The syntheses are shown in Schemes 2.7 and 2.8. This process was especially helpful 
for the synthesis of MV analogues carrying secondary amines having different alkyl 
chains (2.8 and 2.9). Hydrolysis of 2-amino-6-methoxybenzothiazole under strongly 
basic conditions afforded 2-amino-5-methoxybenzothiol which was coupled with 2, 4-
dinitrochlorobenzene to obtain substituted diphenylsulfide intermediate 2.18 in 81% 
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yield.89 Compound 2.18 was treated with acetic anhydride in order to activate the amine 
as acetamide intermediate 2.19. Smiles rearrangement of 2.19 under mildly basic 
conditions afforded the substituted phenothiazine intermediate 2.20 in 90% yield.89 
Compound 2.20 was subsequently protected with a tert-butyloxycarbonyl (Boc) group to 
obtain 2.21 in 86% yield. Hydrogenolysis of 2.21 afforded 2.22, which was alkylated 
with different alkyl iodides/bromides in the presence of Na2CO3 as base to obtain 2.23-
2.29 in varying yields. In order to remove the O-methyl group to afford the free hydroxyl 
group at position 7, compounds 2.23-2.29 were treated with 1 M BBr3 in CH2Cl2. The 
HBr, formed in situ, effected removal of the Boc group at the same time generating the 
desired MV analogues 2.5-2.10 in yields varying from 25% to 54%. 
Scheme 2.7. Synthesis of compounds 2.5-2.7 and 2.10.  
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Scheme 2.8. Synthesis of compounds 2.8 and 2.9.  
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Biochemical and biological evaluation of some choosen analogues 
Cytotoxicity 
    Cytotoxicity was assessed by the dye exclusion method. Live cells have intact 
membranes, which exclude a variety of dyes that easily penetrate the damaged, 
permeable membranes of non-viable cells. Propidium iodide, a membrane impermeant 
dye, is generally excluded from viable cells, although it can enter non-viable cells and 
bind to double-stranded DNA by intercalating between base pairs. Methylene blue 
analogues were tested for their cytotoxicity in FRDA lymphocytes using FACS analysis 
with propidium iodide. The results are depicted in Figure 2.9. From the results it is 
evident that cytotoxicity decreases with increasing lipophilicity in lower as well as higher 
concentrations for both MB and MV analogues. 
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Figure 2.9. Cytotoxicity measurement for the test compounds in cultered FRDA 
lymphocytes. Experiment performed by Dr. Omar Khdour. Compounds IB-I-24 and IB-
I-25 (Figure 2.14) were synthesized by Indrajit Bandyopadhyay. 
 
Suppression of reactive oxygen species 
    The ability of MB analogue 2.1 and MV analogue 2.11 to suppress ROS induced by 
the depletion of cellular glutathione was evaluated in FRDA lymphocytes in a 
quantitative FACS experiment using dichlorofluorescein diacetate (DCFH-DA)90 as an 
indicator of intracellular ROS levels. In cells DCFH-DA is hydrolyzed by esterases to 
afford 2, 7-dichlorodihydrofluorescein (DCFH). The non-fluorescent DCFH can be 
oxidized by cellular oxidants generating fluorescent dichlorofluorescein (DCF). The 
results are shown in Figure 2.10, and demonstrate that compounds 2.1 and 2.11 were 
more potent and effective in protecting FRDA lymphocytes than the parent compounds 
MB and MV, respectively, and did so in a concentration dependent manner.    
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Figure 2.10. Suppression of ROS production by the test compounds in cultured FRDA 
lymphocytes pretreated with DEM. Experiment performed by Dr. Omar Khdour. 
 
Preserving mitochondrial inner membrane potential (ΔΨm) 
 
    The ability of 2.1 and 2.11 to maintain mitochondrial membrane potential (ΔΨm) 
compared to the parent compounds MB and MV was studied.91 ΔΨm was determined 
using the cationic fluorescent dye 5, 5′, 6, 6′-tetrachloro-1, 1′, 3, 3′-
tetraethylbenzimidazolyl carbocyanine iodide (JC-1), which is a lipophilic cation that 
selectively accumulates in mitochondria due to the negative potential across the inner 
mitochondrial membrane. The dye exists as a monomer at low concentrations giving a 
green fluorescence. At higher concentrations the dye forms J-aggregates, which exhibit 
red fluorescence. Therefore, mitochondrial depolarization is indicated by a decrease in 
red/green fluorescence ratio. Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone 
(FCCP), a commonly used uncoupler of oxidative phosphorylation in mitochondria, was  
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Figure 2.11. Flow cytometric analysis showing the effect of the test compounds on Δψm 
in FRDA lymphocyte cells using the ratiometric fluorescent probe JC-1. Red regions 
represent intact mitochondrial membranes with JC-1 aggregates (red fluorescence), 
whereas the gated regions in green depict cells with loss of Δψm. The bar graph shows the 
percentage of cells with intact Δψm calculated using AccuriTM C6 software. Experiment 
performed by Dr. Omar Khdour. 
 
used as a negative control to dissipate the chemiosmotic proton gradient, which results in 
depolarization of mitochondrial membrane potential. Figure 2.11 summarizes the results 
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of this study. Clearly compounds 2.1 and 2.11 were more effective in preserving 
mitochondrial membrane potential than the parent compounds MB and MV. 
Cytoprotection 
    The ability of 2.1 and 2.11 to demonstrate cyotoprotection was measured in FRDA 
lymphocytes.92,93 The cells were treated with rotenone to induce cytotoxicity by 
inhibiting complex I. The results are shown in Figure 2.12. Compounds 2.1 and 2.11 
protected the cells against rotenone cytotoxicity more efficiently than MB and MV, in 
agreement with the earlier studies. 
 
Figure 2.12. Cytoprotective effects of the test compounds on the viability of cultured 
FRDA lymphocytes treated with rotenone. Experiment performed by Dr. Omar Khdour. 
 
Determination of ATP levels 
    ATP levels in FRDA lymphocytes were measured using firefly luciferase.93 The cells 
were grown on glucose-free media supplemented with galactose for 24 h prior to the 
 38   
addition of the test compounds. Since cells grown in galactose rely mostly on oxidative 
phosphorylation (OX-PHOS) to produce their ATP, they become more sensitive to 
mitochondrial respiratory chain inhibitors than cells grown in glucose medium. The 
results are shown in Figure 2.14. MB, MV, IB-I-24 and IB-I-25 strongly reduce cellular 
ATP levels in a concentration dependent manner. Compound 2.11 maintains cellular ATP 
levels in all concentrations. Compounds 2.1 and 2.9 maintain ATP levels upto 2.5 μM 
concentration, beyond that they reduce ATP levels significantly. 
 
Figure 2.13. Total ATP concentration in FRDA lymphocytes, upon incubation with the 
test compounds for 24 and 48 h. Experiment performed by Dr. Omar Khdour. 
Compounds IB-I-24 and IB-I-25 (Figure 2.14) were synthesized by Indrajit 
Bandyopadhyay. 
2.3 Discussion 
    Although there have been numerous reports of synthesis of phenothiazinium 
analogues, most of them lack evidence of purity such as NMR analysis, elemental 
analysis and HPLC analysis.76,78 Strekwoski et al. demonstrated a facile synthesis of 3, 7-
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di(alkylamino)phenothiazinium salts by the oxidation of commercially available 
phenothiazine by iodine followed by the sequential addition of dialkylamines.87 Although 
the final yields of the phenothiazinium salts produced by this method were lower, the 
method was used because of relatively smaller number of steps involved. The synthesis 
of hydrophobic MB analogues was divided into two parts; the addition of long alkyl 
substituent to the phenothiazine core through functional group interconversion followed 
by oxidative addition of the amines. In order to attach a long alkyl substituent on the 
aromatic ring, commercially available 2-cyanophenothiazine was selected as the starting 
material (Scheme 2.2). The secondary amine at position 10 was protected using a tert-
butyloxycarbonyl (Boc) group. This step resulted in a quantitative yield of 2.14. In the 
next step the cyano group at position 2 was converted to an aldehyde by reductive 
hydrolysis. This step gave a 58% yield of the aldehyde 2.15. The aldehyde was then 
converted to an alkene by the Wittig reaction with commercially available 
hexadecyltriphenylphosphonium bromide under strongly basic conditions. The alkene 
was obtained as a cis-trans mixture, which was subsequently reduced to alkane 2.16 by 
hydrogenolysis using palladium-on-carbon (Pd-C) as catalyst. The use of hydrogen at 
atmospheric pressure was not sufficient for the reduction to proceed. Therefore, an 
elevated hydrogen pressure (40 psi) was used along with 20% Pd-C. Compound 2.16 was 
obtained in 74% yield over two steps.  In the subsequent step, the protecting group at 
position 10 was removed using trifluoroacetic acid (TFA) to obtain the 2-
alkylphenothiazine 2.17. This step gave the compound in almost quantitative yield. The 
oxidation and subsequent addition of an amine to the alkylphenothiazine 2.17 could be 
done in one or two steps. A one-step procedure was followed, since in the two-step 
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procedure isolation of the oxidized phenothiazine proved difficult. The MB analogues 
were obtained in low yields ranging from 7% (for 2.4) to 31% (for 2.2) (Schemes 2.2-
2.4). 
    The MV analogues were obtained following two different procedures. Compounds 
2.11, 2.12 and 2.13 were obtained by the basic hydrolysis of MB analogues 2.1, 2.3 and 
2.4 independently, albeit in poor yields. Compounds 2.5-2.10 were synthesized using the 
Smiles rearrangement where functionalized phenothiazines are prepared by the 
intramolecular rearrangement of functionalized diphenyl sulfides under basic conditions 
(Scheme 2.7). The diphenyl sulfide intermediate 2.18 was prepared by the coupling of 2-
amino-5-methoxybenzothiol and 2, 4-dinitrochlorobenzene under mildly acidic condition. 
The highly unstable 2-amino-5-methoxybenzothiol was prepared by the basic hydrolysis 
of 2-amino-5-methoxybenzothiazole at reflux. The thiol was used for the coupling step 
without isolation or further purification from the reaction mixture. The high yield of 2.18 
(81%) indicates the efficient formation of the thiol intermediate. Compound 2.18 was 
then activated as its acetamide derivative (2.19) by treatment with acetic anhydride. 
Smiles rearrangement of 2.19 under mildly basic condition yielded the functionalized 
phenothiazine 2.20 in 90% yield. Subsequently the nitro group at position 7 was reduced 
to afford an aromatic amine, which was alkylated using different alkyl iodides/bromides 
under basic conditions to obtain compounds 2.23-2.29. Removal of the Boc and methyl 
groups by BBr3 afforded the final compounds 2.5-2.10 in varying yields. 
    A number of MB analogues have been designed and synthesized with variations in 
their redox core and their side chain that could enable the compounds to protect against 
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oxidative stress, augment ATP levels and enhance mitochondrial function. The 
preliminary biochemical results for some of the compounds synthesized are presented in  
S
N
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IB-I-24 IB-I-25  
Figure 2.14. Chemical structures of IB-I-24 and IB-I-25. The compounds were 
synthesized by Indrajit Bandyopadhyay. 
 
this thesis. The strong cytoxicity of MB itself in FRDA lymphocytes at 0.5-2.5 µM 
concentrations was surprising, given its long clinical use. A nutrient-sensitized screening 
strategy was used by culturing the FRDA cells on galactose as the sole sugar source, 
forcing them to rely on mitochondrial OX-PHOS to produce their ATP; consequently 
they became more sensitive to respiratory chain inhibitors than cells grown on glucose. 
Figure 2.9 shows that MB was cytotoxic when used at 2.5 μM concentration for 48 h. 
The modified MB/MV analogues with long alkyl side chains (2.1, 2.9 and 2.11) were not 
significantly cytotoxic under any tested condition, although two analogues with shorter 
side chains (IB-I-24 and IB-I-25, Figure 2.14) were somewhat cytotoxic. Shown in 
Figure 2.10 are the abilities of the new MBs to suppress ROS production in FRDA 
lymphocytes depleted of glutathione by using 5 mM diethyl maleate. The MB analogues 
preserved the mitochondrial membrane potential of FRDA lymphocytes. FACS analysis 
of Δψm showed that MB and MV significantly depolarized Δψm, while our analogues did 
not (Figure 2.11). The three long alkyl chain MB analogues also restored ATP levels in 
FRDA lymphocytes (Figure 2.13). In contrast, MB itself inhibited ATP production, 
especially at higher concentrations. The side chain modifications also had a dramatic 
effect on their ability to afford cytoprotection to rotenone-treated FRDA lymphocytes 
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(Figure 2.12). Two other analogues (IB-I-24 and IB-I-25) did not exhibit favorable 
activity in increasing ATP levels (Figure 2.13). 
2.4 Experimental  
    Chemicals and solvents were purchased as reagent grade from Sigma-Aldrich 
Chemicals and were used without further purification. All the reactions were performed 
under an argon atmosphere, unless otherwise specified. Thin-layer chromatography 
(TLC) plates (precoated glass plates with silica gel 60 F254, 0.25 mm thickness) were 
used for analytical TLC and were visualized by UV irradiation (254 nm). Flash 
chromatography was carried out using Silicycle 200−400 mesh silica gel. 1H and 13C 
NMR spectra were obtained using a Varian 400 MHz NMR spectrometer. Chemical 
shifts (δ) are reported in parts per million (ppm) and are referenced to residual CHCl3 (δ 
7.26 ppm for 1H NMR and δ 77.16 for 13C NMR) as the internal strandard. Splitting 
patterns are designated as s, singlet; d, doublet; m, multiplet. High-resolution mass 
spectra were obtained at the Michigan State Mass Spectrometry Facility or the Arizona 
State University CLAS High Resolution Mass Spectrometry Facility. 
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tert-Butyl 2-Cyano-10H-phenothiazine-10-carboxylate (2.14). 0.74 g (3.30 mmol) of 
2-cyanophenothiazine was dissolved in 10 mL of anhydrous DMF. The reaction mixture 
was cooled to 0 oC and 0.40 g (9.90 mmol) of 60% NaH was added. The dark reaction 
mixture was stirred at 0 oC for an additional 15 min and 0.90 g (3.96 mmol) of di-tert-
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butyl dicarbonate was added. The reaction mixture was stirred at room temperature for 3 
h and was diluted with 50 mL of brine. The aqueous layer was extracted with three 25-
mL portions of ethyl acetate. The combined organic extract was dried over anhydrous 
MgSO4 and concentrated under diminished pressure. The crude product was purified on a 
silica gel column (10 × 2 cm). Elution with ethyl acetate_hexanes (1:9) gave 2.14 as a 
pale yellow solid: yield 1.07 g (100%); silica gel TLC Rf 0.26 (1:9 ethyl acetate_hexanes); 
1H NMR (CDCl3) d 1.49 (s, 9H), 7.16-7.20 (m, 1H), 7.28-7.33 (m, 2H), 7.40 (s, 2H), 7.49 
(d, 1H, J = 8.4 Hz) and 7.80 (s, 1H); 13C NMR d 28.1, 83.1, 110.2, 118.2, 126.6, 127.2, 
127.3, 127.5, 128.1,129.1, 130.3, 130.6, 137.7, 139.0, 139.1 and 151.8; mass spectrum 
(APCI), m/z 325.1017 (M+H)+  (C18H17N2O2S requires m/z 325.1011). 
S
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tert-Butyl 2-Formyl-10H-phenothiazine-10-carboxylate (2.15). To a solution of 1.07 g 
(3.30 mmol) of 2.14 in 10 mL of anhydrous CH2Cl2 was added dropwise at _78 oC 4.0 mL 
(4.0 mmol) of 1 M DIBAL-H in toluene. The reaction mixture was stirred at _78 oC for 3 
h and was diluted with ~ 2 N HCl. The aqueous layer was extracted with three 30-mL 
portions of CH2Cl2. The combined organic extract was dried over anhydrous MgSO4 and 
was concentrated under diminished pressure. The residue was purified on a silica gel 
column (7 × 4 cm). Elution with 1:9 ethyl acetate_hexanes afforded 2.15 as a yellow 
solid: yield 0.63 g (58%); silica gel TLC Rf 0.17 (1:9 ethyl acetate_hexanes); 1H NMR 
(CDCl3) d 1.48 (s, 9H), 7.14-7.18 (m, 1H), 7.26-7.32 (m, 2H), 7.44 (d, 1H, J = 8.0 Hz), 
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7.52 (d, 1H, J = 7.4 Hz), 7.64 (d, 1H, J = 8.0 Hz), 7.99 (s, 1H) and 9.96 (s, 1H); 13C 
NMR d 28.1, 82.8, 126.5, 126.6, 127.1, 127.3, 127.4, 127.8, 128.3, 130.5, 135.1, 137.9, 
139.1, 140.2 and 152.1; mass spectrum (ESI), m/z 328.1003 (M+H)+  (C18H18NO3S 
requires m/z 328.1007). 
S
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tert-Butyl 2-Heptadecyl-10H-phenothiazine-10-carboxylate (2.16). To a solution of 
0.64 g (1.13 mmol) of hexadecyltriphenylphosphonium bromide in 5 mL of anhydrous 
THF at _78 oC was added dropwise 1.20 mL (1.20 mmol) of 1 M sodium bis-
(trimethylsilyl)amide in THF. The yellow reaction mixture was stirred at 0 oC for 3 h and 
was cooled to _78 oC. To this bright orange suspension was added dropwise 0.37 g (1.13 
mmol) of 2.15 dissolved in 5 mL of anhydrous THF. The light yellow reaction mixture 
was stirred at 0 oC under an argon atmosphere overnight and was then diluted with 50 mL 
of brine. The aqueous layer was extracted with three 25-mL portions of ethyl acetate. The 
combined organic extract was dried over anhydrous MgSO4 and was concentrated under 
diminished pressure. The residue was purified on a silica gel column. Elution with 1:9 
CH2Cl2_hexanes yielded a cis-trans mixture as a colorless solid. 
    To a solution of 0.41 g (0.77 mmol) of the cis-trans mixture in 3:7 CH2Cl2_ethanol was 
added 26 mg of palladium on carbon. The suspension was stirred at room temperature 
under a H2 atmosphere (40 psi) for 2 h. The reaction mixture was filtered through a Celite 
pad. The filtrate was concentrated under diminished pressure to afford 2.16 as a colorless 
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solid: yield 0.41 g (74% over two steps); silica gel TLC Rf 0.1 (1:9 CH2Cl2_hexanes); 1H 
NMR (CDCl3) d 0.88 (t, 3H, J = 7.0 Hz), 1.26-1.30 (m, 28H), 1.49 (s, 9H), 1.60 (t, 2H, J 
= 7.2 Hz), 2.59 (t, 2H, J = 7.6 Hz), 6.96 (d, 1H, J = 7.6 Hz), 7.12 (t, 1H, J = 7.6 Hz), 
7.21-7.26 (m, 2H), 7.32-7.35 (m, 2H) and 7.52 (d, 1H, J = 7.6 Hz); 13C NMR (CDCl3) 
d 14.3, 22.9, 28.4, 29.5, 29.53, 29.70, 29.74, 29.84, 29.87, 31.7, 32.1, 35.8, 82.0, 126.1, 
126.5, 126.6, 127.2, 127.33, 127.37, 127.6, 128.9, 132.7, 138.8, 139.0, 142.0 and 152.7; 
mass spectrum (APCI), m/z 538.3723 (M+H)+  (C34H52NO2S requires m/z 538.3719). 
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N-(7-(Dimethylamino)-2-heptadecyl-3H-phenothiazin-3-ylidene)-N-
methylmethanaminium Iodide (2.1). To a solution of 0.23 g (0.43 mmol) of 2.16 in 8 
mL of anhydrous CH2Cl2 was added dropwise 0.26 mL (0.39 g, 3.44 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 12 h under 
an argon atmosphere and was neutralized with 50 mL of saturated NaHCO3 solution. The 
aqueous layer was extracted with three 30-mL portions of CH2Cl2. The combined organic 
layer was dried over anhydrous MgSO4 and was concentrated under diminished pressure. 
The crude (2.17) was utilized in the next step without further purification. 
    To a solution of 45 mg of the crude 2.17 in 5 mL of CH2Cl2 was added 81.0 mg (0.32 
mmol) of iodine followed by 0.25 mL (0.50 mmol) of 2 M dimethylamine in THF. The 
reaction mixture was stirred at room temperature under an argon atmosphere for 12 h. 
The crude product was purified on a silica gel column (10 × 2 cm). Elution with ethyl 
acetate afforded 2.1 as a green solid: yield 18 mg (28%); silica gel TLC Rf 0.40 (ethyl 
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acetate); 1H NMR (CDCl3) d 0.86 (t, 3H, J = 6.6 Hz), 1.15-1.37 (m, 28H), 1.69-1.72 (m, 
2H), 2.81-2.85 (m, 2H), 3.33 (s, 6H), 3.46 (s, 6H), 7.36-7.38 (m, 1H), 7.41 (s, 1H), 7.76 
(m, 1H), 7.89 (s, 1H) and 7.99 (d, 1H, J = 7.6 Hz); 13C NMR (CDCl3) δ 14.2, 22.8, 29.4, 
29.7, 29.72, 29.74, 29.76, 29.79, 30.3, 32.0, 34.1, 34.9, 42.6, 44.7, 107.5, 111.6, 119.9, 
132.2, 135.9, 137.1, 137.4, 138.5, 138.9, 154.2 and 158.1; mass spectrum (APCI), m/z 
522.3882 (M)+  (C33H52N3S requires m/z 522.3882). 
S
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N-(4,7-bis(Dimethylamino)-2-heptadecyl-3H-phenothiazin-3-ylidene)-N-
methylmethanaminium Iodide (2.2). To a solution 0.10 g of the crude 2.17 in 5 mL of 
CH2Cl2 was added 0.19 g (0.74 mmol) of iodine followed by 1.15 mL (2.30 mmol) of 2 
M dimethylamine in THF. The reaction mixture was heated at 45 oC under an argon 
atmosphere for 7 h. The blue reaction mixture was purified on a silica gel column (10 × 2 
cm). Elution with 20% methanol in ethyl acetate afforded 2.2 as a blue solid: yield 40 mg 
(31%); silica gel TLC Rf 0.35 (4:1 ethyl acetate_methanol); 1H NMR (CDCl3) d 0.86 (t, 
3H, J = 6.8 Hz), 1.24-1.44 (m, 28H), 1.61-1.63 (m, 2H), 2.71 (m, 2H), 3.28 (s, 6H), 3.30 
(s, 6H), 3.49 (s, 6H), 6.17 (s, 1H), 6.89 (d, 1H, J = 2.8 Hz), 7.05 (dd, 1H, J = 9.2 Hz, J = 
2.4 Hz) and 7.78 (d, 1H, J = 9.6 Hz); 13C NMR δ 14.3, 22.8, 26.4, 29.5, 29.8, 29.82, 
29.85, 30.1, 30.7, 32.1, 41.4, 44.7, 45.9, 51.0, 101.3, 105.6, 115.8, 121.5, 130.6, 131.1, 
132.2, 133.8, 137.0, 153.5 and 161.1; mass spectrum (MALDI-TOF), m/z 565.4135 (M)+  
(C35H57N4S requires m/z 565.4298). 
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7-(Dimethylamino)-2-heptadecyl-3H-phenothiazin-3-one (2.11). To a dark green 
solution of 70.0 mg (0.09 mmol) of 2.1 in 3.5 mL THF_H2O (6:1) was added 30.0 mg 
(0.53 mmol) of KOH. The reaction mixture was stirred for 2 min at room temperature 
until it changes from green to red. The aqueous layer was extracted with two 10-mL 
portions of ethyl acetate. The combined organic layer was dried over anhydrous MgSO4 
and was concentrated under diminished pressure. The crude product was purified on a 
silica gel column (7 × 2 cm). Elution with 2:3 ethyl acetate_hexanes yielded 2.11 as a 
violet solid: yield 11 mg (24%); silica gel TLC Rf 0.59 (2:3 ethyl acetate_hexanes); 1H 
NMR (CDCl3) δ 0.86-0.89 (m, 3H), 1.27-1.41 (m, 28H), 1.72 (t, 2H, J = 6.0 Hz), 2.72 (t, 
2H, J = 6.4 Hz), 2.89 (s, 6H), 6.73 (d, 1H, J = 1.6 Hz), 6.89 (dd, 1H, J = 7.6 Hz, J = 2.0 
Hz), 6.93 (s, 1H), 7.60 (d, 1H, J = 8.0 Hz) and 7.71 (s, 1H); 13C NMR (CDCl3) δ 14.3, 
22.8, 29.5, 29.6, 29.7, 29.81, 29.85, 30.1, 31.6, 32.1, 44.0,112.8,119.3, 123.3, 134.0, 
134.6, 135.5, 136.4, 139.7, 143.3, 155.8 and 182.5; mass spectrum (ESI), m/z 495.3414 
(M+H)+  (C31H47N2OS requires m/z 495.3409). 
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1-(2-Heptadecyl-7-(piperidin-1-yl)-3H-phenothiazin-3-ylidene)piperidin-1-ium 
Iodide (2.3). 30.0 mg (0.07 mmol) of crude 2.17 was dissolved in 5 mL of CH2Cl2 and 
56.0 mg (0.22 mmol) of I2 was added followed by piperidine 34.0 μL (29.0 mg, 0.35 
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mmol). The reaction mixture was stirred at room temperature for 3 h under an argon 
atmosphere and was purified on a silica gel column (8 × 2 cm). Elution with ethyl acetate 
gave 2.3 as a green solid: yield 5 mg (10%); silica gel TLC Rf 0.43 (ethyl acetate); 1H 
NMR (CDCl3) δ 0.87 (t, 3H, J = 6.8 Hz), 1.25 (br s, 30H), 1.73-1.90 (m, 14H), 2.72 (t, 
2H, J = 7.8 Hz), 3.38-3.40 (m, 3H), 3.94-3.96 (m, 3H), 7.47 (s, 1H), 7.56 (dd, 1H, J = 9.8 
Hz, J =2.6 Hz), 7.65 (d, 1H, J = 2.4 Hz), 7.92 (s, 1H) and 7.98 (d, 1H, J = 10 Hz); 13C 
NMR (CDCl3) δ 14.3, 22.8, 24.0, 26.2, 27.0, 29.5, 29.54, 29.7, 29.78, 29.8, 29.83, 30.5, 
32.1, 32.1, 50.9, 53.4, 107.8, 110.1, 113.7, 121.2, 130.5, 137.4, 139.1, 139.6, 139.9, 153.4 
and 158.8; mass spectrum (ESI), m/z 602.4496 (M)+  (C39H60N3S requires m/z 602.4508). 
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2-Heptadecyl-7-(piperidine-1-yl)-3H-phenothiazin-3-one (2.12). To a dark green 
solution of 60.0 mg (0.10 mmol) of 2.3 in 3.5 mL THF_H2O (6:1) was added 16.0 mg 
(0.30 mmol) of KOH. The reaction mixture was stirred for 2 min at room temperature 
until it changes from green to red. The aqueous layer was extracted with two 10-mL 
portions of ethyl acetate. The combined organic layer was dried over anhydrous MgSO4 
and was concentrated under diminished pressure. The crude product was purified on a 
silica gel column (7 × 2 cm). Elution with 1:4 ethyl acetate_hexanes yielded 2.12 as a 
brownish solid: yield 12.3 mg (22%); silica gel TLC Rf 0.75 (3:2 ethyl acetate_hexanes); 
1H NMR (CDCl3) δ 0.88 (t, 3H, J = 5.6 Hz), 1.26 (br s, 30H), 1.62-1.78 (m, 7H), 2.35 (t, 
1H, J = 6.0 Hz), 2.66 (t, 2H, J = 6.4 Hz), 2.97-2.99 (m, 2H), 6.73 (d, 1H, J = 1.6 Hz), 
6.87 (dd, 1H, J = 12 Hz, J = 2.0 Hz), 6.96 (s, 1H), 7.60 (d, 1H, J = 9.6 Hz) and 7.72 (s, 
 49   
1H); 13C NMR (CDCl3) δ 14.1, 22.6, 22.7, 24.1, 26.1, 29.3, 29.4, 29.5, 29.54, 29.6, 29.63, 
29.67, 30.2, 30.5, 31.6, 31.9, 53.5, 114.1 119.1, 122.9, 134.0, 134.9, 135.0, 137.0, 139.6, 
143.6, 156.1 and 182.3; mass spectrum (ESI), m/z 535.3731 (M+H)+  (C34H51N2OS 
requires m/z 535.3722). 
S
N
NN
I
+
OO
 
4-(2-Hexadecyl-7-morpholino-3H-phenothiazin-3-ylidine)morpholin-4-ium Iodide 
(2.4). 44.0 mg (0.10 mmol) of crude 2.17 was dissolved in 5 mL of CH2Cl2 and 81.0 mg 
(0.32 mmol) of I2 was added followed by morpholine 47.0 μL (47.0 mg, 0.50 mmol). The 
reaction mixture was stirred at room temperature for 3 h under an argon atmosphere and 
was purified on a silica gel column (8 × 2 cm). Elution with ethyl acetate gave 2.4 as a 
green solid: yield 5 mg (7%); silica gel TLC Rf 0.43 (ethyl acetate); 1H NMR (CDCl3) δ 
0.88 (t, 3H, J = 6.8 Hz), 1.24-1.40 (m, 30H), 1.76-1.80 (m, 7H), 2.76 (t, 2H, J = 7.8 Hz), 
3.43-3.45 (m, 3H), 3.92-3.98 (m, 6H), 7.56 (s, 1H), 7.61-7.64 (m, 1H), 7.69 (d, 1H, J = 
2.0 Hz), 8.06 (s, 1H) and 8.13 (d, 1H, J = 9.6 Hz); 13C NMR (CDCl3) δ 14.1, 22.7, 29.3, 
29.4, 29.5, 29.6, 29.7, 30.1, 30.9, 31.9, 32.1, 48.9, 52.3, 66.6, 107.7, 113.7, 121.2, 130.9, 
137.6, 137.9, 139.7, 139.8, 140.1, 153.9 and 157.9; mass spectrum (ESI), m/z 606.4113 
(M)+  (C37H56N3O2S requires m/z 606.4093). 
S
N
ON
O
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2-Heptadecyl-7-(morpholine-1-yl)-3H-phenothiazin-3-one (2.13). To a dark green 
solution of 58.0 mg (0.10 mmol) of 2.4 in 3.5 mL THF_H2O (6:1) was added 11.0 mg 
(0.19 mmol) of KOH. The reaction mixture was stirred for 2 min at room temperature 
until it changes from green to red. The aqueous layer was extracted with two 10-mL 
portions of ethyl acetate. The combined organic layer was dried over anhydrous MgSO4 
and was concentrated under diminished pressure. The crude product was purified on a 
silica gel column (7 × 2 cm). Elution with 1:4 ethyl acetate_hexanes yielded 2.13 as a 
brownish solid: yield 7 mg (14%); silica gel TLC Rf 0.75 (3:2 ethyl acetate_hexanes); 1H 
NMR (CDCl3) δ 0.86 (m, 3H), 1.21-1.38 (m, 28H), 1.69-1.70 (m, 2H), 2.67 (t, 2H, J = 
8.0 Hz), 2.99-3.02 (m, 4H), 3.86-3.88 (m, 4H), 6.72 (d, 1H, J = 2.0 Hz), 6.89 (dd, 1H, J = 
10.2 Hz, J = 2.2 Hz), 6.97 (s, 1H), 7.58 (d, 1H, J = 10 Hz) and 7.74 (s, 1H); 13C NMR 
(CDCl3) δ 14.3, 22.8, 29.5, 29.6, 29.7, 29.8, 29.85, 30.4, 30.6, 32.1, 52.6, 67.1, 114.6, 
119.6, 122.9, 134.5, 135.2, 135.4, 135.7, 138.0, 144.6, 154.5 and 182.4; mass spectrum 
(ESI), m/z 537.3518 (M+H)+  (C33H49N2O2S requires m/z 537.3515). 
S
NH2 NO2 NO2
MeO
 
2-(2,4-Dinitrophenyl)thio)-5-methoxyaniline (2.18). 2.00 g (11.1 mmol) of 2-amino-6-
methoxybenzothiazole was suspended in 40 ml of water and 9.30 g (167 mmol) of solid 
KOH was added. The suspension was heated to reflux for 12 h. The reaction mixture was 
cooled to room temperature and added dropwise to a solution of 2.25 g (11.1 mmol) of 2, 
4-dinitrochlorobenzene in a mixture of ethanol (30 mL)_AcOH (20 mL) in ice_water bath. 
The reaction mixture was stirred at room temperature for an additional 3 h. The 
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precipitate was filtered, washed with water_ethanol (1:1, v/v) and dried to afford 2.18 as 
an orange solid: yield 2.90 g (81%); silica gel TLC Rf 0.7 (3:7 ethyl acetate_hexanes); 1H 
NMR (CD3COCD3) δ 3.76 (s, 3H), 6.85 (d, 1H, J = 8.8 Hz), 6.97 (d, 1H, J = 2.8 Hz), 
7.00-7.06 (m, 2H), 8.18 (dd, 1H, J = 9.2 Hz, J = 2.6 Hz) and 9.12 (d, 1H, J = 2.4 Hz); 13C 
NMR (DMSO-d6) δ 55.9, 111.0, 117.5, 120.4, 120.6, 121.6, 127.1, 128.6, 143.3, 144.4, 
144.6, 145.8 and 153.0; mass spectrum (APCI), m/z 322.0499 (M + H)+ (C13H12N3O5S 
requires m/z 322.0498).  
S
NH NO2 NO2
O
O
 
N-(2-((2,4-Dinitrophenyl)thio)-5-methoxyphenyl)acetamide (2.19). To a solution of 
2.90 g (9.03 mmol) of 2.18 in 10 mL of anhydrous DMF was added 3.66 mL (2.74 g, 
27.1 mmol) of anhydrous triethylamine followed by 4.30 mL (4.64 g, 45.5 mmol) of 
acetic anhydride. The reaction mixture was stirred for 12 h at room temperature under an 
argon atmosphere and was quenched by pouring into ice-cold water. The aqueous layer 
was extracted with four 25-mL portions of ethyl acetate. The combined organic layer was 
dried over anhydrous MgSO4, filtered and concentrated under diminished pressure. The 
residue was purified on a silica gel column (8 × 4 cm). Elution with 3:7 ethyl 
acetate_hexanes afforded 2.19 as a bright yellow solid: yield 2.95 g (90%); silica gel TLC 
Rf 0.57 (3:7 ethyl acetate_hexanes); 1H NMR (DMSO-d6) δ 1.86 (s, 3H), 3.77 (s, 3H), 
6.99 (d, 1H, J = 8.8 Hz), 7.18 (dd, 1H, J = 8.8 Hz, J = 2.4 Hz), 7.23 (d, 1H, J = 2.8 Hz), 
7.66 (d, 1H, J = 8.8 Hz), 8.32 (dd, 1H, J = 9.0 Hz, J = 2.6 Hz), 8.88 (d, 1H, J = 2.4 Hz) 
and 9.43 (br s, 1H); 13C NMR (DMSO-d6) δ 22.8, 55.6, 117.7, 120.5, 121.0, 123.8, 127.5, 
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128.1, 129.2, 133.7, 144.05, 144.07, 145.6, 157.2 and 168.7; mass spectrum (APCI), m/z 
364.0609 (M + H)+ (C15H14N3O6S requires m/z 364.0603).  
S
H
N
O2N O  
3-Methoxy-7-nitro-10H-phenothiazine (2.20). To a stirred solution of 2.95 g (8.13 
mmol) of 2.19 in 20 mL of acetone, at reflux, was added in portions 0.91 g (16.2 mmol) 
of KOH in 10 mL of ethanol. The reaction mixture was kept at reflux for an additional 3 
h and poured into ice-cold water. The aqueous layer was extracted with four 25-mL 
portions of ethyl acetate. The combined organic layer was dried over anhydrous MgSO4, 
filtered and concentrated under diminished pressure. The residue was purified on a silica 
gel column (8 × 2 cm). Elution with 1:1 ethyl acetate_hexanes gave 2.20 as a violet solid: 
yield 2.00 g (90%); silica gel TLC Rf 0.43 (3:7 ethyl acetate_hexanes); 1H NMR 
(CD3COCD3) δ 3.70 (s, 3H), 6.57-6.70 (m, 4H), 7.73 (d, 1H, J = 2.4 Hz), 7.81-7.84 (m, 
1H) and 8.47 (br s, 1H); 13C NMR (CD3COCD3) δ 55.0, 111.7, 113.0, 113.3, 116.1, 
117.0, 117.2, 121.6, 124.2, 132.4, 141.5, 148.3 and 156.6; mass spectrum (APCI), m/z 
275.0488 (M + H)+ (C13H11N2O3S requires m/z 275.0490). 
S
N
O2N OMe
O O
 
tert-Butyl 3-Methoxy-7-nitro-10H-phenothiazin-10-carboxylate (2.21). To a solution 
of 1.42 g (5.18 mmol) of 2.20 in 20 mL of anhydrous DMF at 0 oC was added 0.55 g 
(13.7 mmol) of 60% NaH. The reaction mixture was stirred at 0 oC for another 15 min 
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and 2.40 g (11.0 mmol) of di-tert-butyl dicarbonate was added. The reaction mixture was 
stirred at room temperature for 4 h under an arogon atmosphere, and was quenched with 
30 mL of water. The aqueous layer was extracted with three 20-mL portions of ethyl 
acetate. The combined organic layer was washed with 20 mL of brine, dried over 
anhydrous MgSO4 and concentrated under diminished pressure. The residue was purified 
on a silica gel column (8 × 4 cm). Elution with 3:7 ethyl acetate_hexanes afforded 2.21 as 
a bright yellow solid: yield 1.66 g (86%); silica gel TLC Rf  0.54 (3:7 ethyl 
acetate_hexanes); 1H NMR (CD3COCD3) δ 1.54 (s, 9H), 3.86 (s, 3H), 6.97 (dd, 1H, J = 
9.2 Hz, J = 2.8 Hz), 7.01 (d, 1H, J = 2.8 Hz), 7.47 (d, 1H, J = 9.2 Hz), 7.84 (d, 1H, J = 
8.8 Hz), 8.20 (dd, 1H, J = 9.0 Hz, J = 2.6 Hz) and 8.24 (d, 1H, J = 2.4 Hz); 13C NMR 
(CD3COCD3) δ 29.2, 57.1, 84.3, 113.3, 115.6, 123.7, 124.1, 129.8, 130.0, 132.3, 133.1, 
135.3, 146.9, 147.1, 153.2 and 159.9; mass spectrum (APCI), m/z 374.0932 (M + H)+ 
(C18H19N2O5S requires m/z 374.0936). 
S
N
H2N OMe
O O
 
tert-Butyl 3-Amino-7-methoxy-10H-phenothiazin-10-carboxylate (2.22). To a 
suspension of  0.42 g (1.12 mmol) of 2.21 in 10 mL of ethanol was added 10 mg of 10% 
Pd on carbon. The reaction mixture was stirred at room temperature under a hydrogen 
atmosphere (25 psi) overnight. The reaction mixture was filtered through a Celite pad and 
was concentrated under diminished pressure. The crude product (2.22) was used for the 
next reaction without further purification. 
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N
N OMe
O O
 
tert-Butyl 3-(N,N-Dibutylamino)-7-methoxy-10H-phenothiazin-10-carboxylate 
(2.23). To a solution of crude 2.22 in 3 mL of acetonitrile was added 1.40 g (12.8 mmol) 
of Na2CO3 followed by 0.94 g (5.12 mmol) of 1-iodobutane. The reaction mixture was 
sealed under nitrogen atmosphere and stirred at 80 oC overnight. The reaction mixture 
was cooled to room temperature and filtered. The filtrate was concentrated under 
diminished pressure and purified on a silica gel column (10 x 2 cm). Elution with 1:9 
ethyl acetate_hexanes gave compound 2.23 as a pale yellow solid: yield 0.31 g (61%); 
silica gel TLC Rf 0.43 (1:9 ethyl acetate_hexanes); 1H NMR (CDCl3) δ 0.95 (t, 6H, J = 
7.4 Hz), 1.32-1.37 (m, 4H), 1.49 (s, 9H), 1.51-1.57 (m, 4H), 3.23 (t, 4H, J = 7.6 Hz), 3.78 
(s, 3H), 6.52-6.55 (m, 2H), 6.78 (dd, 1H, J = 8.8 Hz, J  = 2.8 Hz), 6.86 (d, 1H, J = 2.8 
Hz), 7.31 (d, 1H, J = 8.4 Hz) and 7.39 (d, 1H, J = 8.8 Hz); 13C NMR (CDCl3) δ 13.9, 
20.2, 28.1, 29.2, 50.8, 55.5, 81.2, 109.1, 110.2, 111.5, 112.6, 126.8, 127.2, 127.5, 132.3, 
132.5, 133.2, 146.2, 153.2 and 157.0; mass spectrum (APCI), m/z 457.2530 (M + H)+ 
(C26H37N2O3S requires m/z 457.2525). 
S
N
ON  
7-(N,N-Dibutylamino)-3H-phenothiazin-3-one (2.5). To a solution of 86.0 mg (0.19 
mmol) of 2.23 in 2 mL of anhydrous CH2Cl2 was added dropwise 0.76 mL (0.76 mmol) 
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of 1 M BBr3 in CH2Cl2 at _78 oC. The reaction mixture was stirred overnight at room 
temperature under an argon atmosphere and was quenched with 10 mL of water. The 
aqueous layer was extracted with two 10-mL portions of ethyl acetate. The combined 
organic layer was washed with 10 mL of brine, dried over anhydrous MgSO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column 
(7 x 2 cm). Elution with 1:1 ethyl acetate_hexanes afforded 2.5 as a violet solid: yield 30 
mg (47%); silica gel TLC Rf 0.42 (1:1 ethyl acetate_hexanes); 1H NMR (CDCl3) δ 0.95 (t, 
6H, J = 7.4 Hz), 1.26-1.37 (m, 4H), 1.51-1.57 (m, 4H), 3.23 (m, 4H), 6.52-6.55 (m, 2H), 
6.76-6.87 (m, 2H), 7.31 (d, 1H, J = 8.8 Hz) and 7.38 (d, 1H, J = 8.8 Hz); mass spectrum 
(APCI), m/z 341.1690 (M + H)+ (C20H25N2OS requires m/z 341.1688). 
S
N
N OMe
O O
 
tert-Butyl 3-(N,N-Didecylamino)-7-methoxy-10H-phenothiazin-10-carboxylate 
(2.24). 0.74 g (2.90 mmol) of 1-iododecane in 2 mL of acetonitrile was added into a 
mixture of 0.40 g (~ 1.16 mmol) of crude 2.22 in 2 mL of acetonitrile and 1.23 g (11.6 
mmol) of Na2CO3. The reaction mixture was sealed under nitrogen atmosphere and 
stirred at 80 oC for ~ 48 h. The reaction mixture was cooled to room temperature and 
filtered. The filtrate was concentrated under diminished pressure and purified on a silica 
gel column (8 x 2 cm). Elution with 1:19 ethyl acetate_hexanes gave compound 2.24 as a 
pale yellow solid: yield 30 mg (5%); silica gel TLC Rf 0.41 (1:19 ethyl acetate_hexanes) 
1H NMR (CDCl3) δ 0.81 (t, 6H, J = 6.8 Hz), 1.19 ( m, 28H), 1.22 (s, 9H), 1.40-1.46 (m, 
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4H), 3.13 (t, 4H, J = 7.6 Hz), 3.69 (s, 3H), 6.42-6.44 (m, 2H), 6.90 (dd, 1H, J = 8.6 Hz, J 
= 2.6 Hz), 6.70 (d, 1H, J = 2.8 Hz), 7.21 (d, 1H, J = 8.4 Hz) and 7.30 (d, 1H, J = 8.8 Hz);  
13C NMR (CDCl3) δ 14.1, 22.7, 27.1, 28.2, 29.3, 29.5, 29.6, 31.9, 51.2, 55.5, 81.2, 109.1, 
110.2, 111.6, 112.6, 126.8, 127.3, 127.6, 132.4, 132.6, 133.2, 146.3, 153.3 and 157.1; 
mass spectrum (APCI), m/z 625.4390 (M + H)+ (C38H61N2O3S requires m/z 625.4403). 
S
N
ON
 
7-(N,N-Didecylamino)-3H-phenothiazin-3-one (2.6). 0.20 mL (0.20 mmol) of 1 M 
BBr3 in CH2Cl2 was added dropwise into a solution of 30.0 mg (0.05 mmol) of 
compound 2.24 in 4 mL of CH2Cl2 at _78 oC. The reaction mixture was stirred overnight 
at ambient temperature and was quenched with 10 mL of water. The product was 
extracted with two 10-mL portions of ethyl acetate. The violet organic layer was washed 
with 20 mL of brine, dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. The resulting violet solid was purified on a silica gel column (7 x 2 cm). Elution 
with 1:2 ethyl acetate_hexanes afforded 2.6 as a violet solid: yield 9 mg (38%); silica gel 
TLC Rf  0.50 (1:2 ethyl acetate_hexanes); 1H NMR (CDCl3) δ 0.87 (t, 6H, J = 6.8 Hz), 
1.24-1.34 (m, 28H), 1.63 (br s, 4H), 3.36 (t, 4H, J = 7.8 Hz), 6.51 (d, 1H, J = 2.8 Hz), 
6.66 (d, 1H, J = 2.0 Hz), 6.75-6.82 (m, 2H), 7.53 (d, 1H, J = 9.6 Hz) and 7.46 (d, 1H, J = 
9.2 Hz); 13C NMR (CDCl3) δ 14.1, 22.6, 27.0, 27.3, 29.3, 29.4, 29.50, 29.54, 29.7, 31.8, 
51.4, 104.7, 113.2, 118.4, 128.6, 130.9, 132.1, 134.8, 135.9, 139.4, 139.6, 149.8 and 
182.1; mass spectrum (APCI), m/z 509.3553 (M + H)+ (C32H49N2OS requires m/z 
509.3566). 
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tert-Butyl 3-(N,N-Dipentadecylamino)-7-methoxy-10H-phenothiazin-10-carboxylate 
(2.25). 0.98 g (2.90 mmol) of 1-iodopentadecane in 2 mL of acetonitrile was added into a 
mixture of 0.40 g (~ 1.16 mmol) of crude 2.22 in 2 mL of acetonitrile and 1.23 g (11.6 
mmol) of Na2CO3. The reaction mixture was sealed under nitrogen atmosphere and 
stirred at 80 oC for ~ 48 h. The reaction mixture was cooled to room temperature and 
filtered. The filtrate was concentrated under diminished pressure and purified on a silica 
gel column to remove the unreacted starting material (8 x 2 cm). Elution with 1:19 ethyl 
acetate_hexanes gave a mixture of mono and dialkylated product as a yellow oil. 
S
N
ON
 
7-(N,N-Dipentadecylamino)-3H-phenothiazin-3-one (2.7). 0.28 mL (0.28 mmol) of 1 
M BBr3 in CH2Cl2 was added dropwise into the solution of 50.0 mg of crude compound 
2.25 in 2 mL of CH2Cl2 at _78 oC. The reaction mixture was stirred overnight at ambient 
temperature and was quenched with 10 mL of water. The product was extracted with two 
10-mL portions of ethyl acetate. The combined organic layer was washed with 20 mL of 
brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The 
resulting violet solid was purified on a silica gel column. Elution with 1:4 ethyl 
acetate_hexanes afforded 2.7 as a violet solid: yield 20 mg (44%); silica gel TLC Rf  0.50 
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(1:4 ethyl acetate_hexanes); 1H NMR (CDCl3) δ 0.88 (t, 6H, J = 6.8 Hz), 1.26-1.35 (m, 
48H), 1.62-1.64 (m, 4H), 3.37 (t, 4H, J = 7.6 Hz), 6.53 (d, 1H, J = 2.8 Hz), 6.67 (d, 1H, J 
= 2.0 Hz), 6.76-6.84 (m, 2H), 7.55 (d, 1H, J = 9.6 Hz) and 7.66 (d, 1H, J = 9.2 Hz); 13C 
NMR (CDCl3) δ 14.3, 22.8, 27.1, 27.5, 29.50, 29.53, 29.6, 29.7, 29.77, 29.79, 29.81, 
29.83, 32.1, 51.5, 104.8, 113.3, 118.7, 128.7, 131.0, 132.4, 134.9, 136.0, 139.6, 140.0, 
150.0 and 182.4; mass spectrum (APCI), m/z 648.5144 (M + H)+ (C42H69N2OS requires 
m/z 649.5131). 
S
N
N
H
OMe
O O
 
tert-Butyl 3-(N-Pentadecylamino)-7-methoxy-10H-phenothiazin-10-carboxylate 
(2.27). 2.11 g (7.25 mmol) of 1-bromopentadecane in 3 mL of acetonitrile was added into 
a mixture of 0.50 g (~ 1.45 mmol) of crude compound 2.22 in 2 mL of acetonitrile and 
1.55 g (14.6 mmol) of Na2CO3. The reaction mixture was sealed under nitrogen 
atmosphere and stirred at 80 oC for ~ 3 days. The reaction mixture was cooled to room 
temperature and filtered. The filtrate was concentrated under diminished pressure and 
purified on a silica gel column. Elution with 1:9 ethyl acetate_hexanes gave compound 
2.27 as a pale yellow solid: yield 0.14 g (9%); silica gel TLC Rf 0.31 (1:9 ethyl 
acetate_hexanes); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 6.6 Hz), 1.25 ( br s, 24H), 1.45 (s, 
9H), 1.52-1.57 (m, 2H), 3.04 (t, 2H, J = 7.2 Hz), 3.76 (s, 3H), 6.45 (dd, 1H, J = 8.6 Hz, J 
= 2.6 Hz), 6.50 (d, 1H, J = 2.8 Hz),  6.76 (dd, 1H, J = 8.8 Hz, J = 2.8 Hz), 6.83 (d, 1H, J 
= 2.8 Hz), 7.24 (d, 1H, J = 8.4 Hz) and 7.36 (d, 1H, J = 8.8 Hz);  13C NMR (CDCl3) δ 
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14.2, 22.8, 27.2, 28.20, 28.27, 28.31, 28.4, 29.46, 29.5, 29.69, 29.70, 29.75, 29.8, 32.0, 
44.2, 55.7, 81.4, 109.8, 111.65, 111.7, 112.8, 127.6, 127.8, 128.7, 132.5, 132.7, 133.3, 
146.7, 153.3 and 157.3; mass spectrum (APCI), m/z 555.3629 (M + H)+ (C33H51N2O3S 
requires m/z 555.3620). 
S
N
N OMe
O O
 
tert-Butyl 3-(N-Methyl-N-pentadecylamino)-7-methoxy-10H-phenothiazin-10-
carboxylate (2.28). 7.00 µL (16.0 mg, 0.11 mmol) of iodomethane was added into a 
mixture of 53.0 mg (0.10 mmol) of compound 2.27 in 2 mL of acetonitrile and 16.0 mg 
(0.15 mmol) of Na2CO3. The reaction mixture was sealed under nitrogen atmosphere and 
stirred at 80 oC for ~ 16 h. The reaction mixture was cooled to room temperature and 
filtered. The filtrate was concentrated under diminished pressure. The crude was used to 
the next step without further purification. 
S
N
ON  
7-(N-Methyl-N-pentadecylamino)-3H-phenothiazin-3-one (2.8). 0.27 mL (0.27 mmol) 
of 1 M BBr3 in CH2Cl2 was added dropwise into the solution of 50.0 mg of crude 2.28 in 
2 mL of CH2Cl2 at _78 oC. The reaction mixture was stirred overnight at room 
temperature and was quenched with 10 mL of water. The product was extracted with two 
10-mL portions of ethyl acetate. The combined organic layer was washed with 20 mL of 
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brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The 
resulting violet solid was purified on a silica gel column (7 x 2 cm). Elution with 3:7 
ethyl acetate_hexanes afforded 2.8 as a violet solid: yield 22 mg (54%); silica gel TLC Rf  
0.50 (1:4 ethyl acetate_hexanes); 1H NMR (CDCl3) δ 0.86 (t, 3H, J = 6.4 Hz), 1.24-1.32 
(m, 24H), 1.60-1.65 (m, 2H), 3.09 (s, 3H), 3.37 (t, 2H, J = 7.6 Hz), 6.55 (d, 1H, J = 2.8 
Hz), 6.68 (d, 1H, J = 2.4 Hz), 6.80-6.84 (m, 2H), 7.54 (d, 1H, J = 9.6 Hz) and 7.67 (d, 
1H, J = 9.2 Hz); 13C NMR (CDCl3) δ 14.2, 22.6, 27.1, 27.4, 29.50, 29.55, 29.6, 29.7, 
29.77, 29.78, 29.81, 29.83, 51.5, 104.8, 113.3, 118.7, 128.7, 131.0, 132.4, 134.8, 136.1, 
139.6, 140.2, 150.0 and 182.4; mass spectrum (APCI), m/z 453.2947 (M + H)+ 
(C28H41N2OS requires m/z 453.2940). 
S
N
N OMe
O O
 
tert-Butyl 3-(N-Butyl-N-pentadecylamino)-7-methoxy-10H-phenothiazin-10-
carboxylate (2.29). 0.11 mL (0.14 g, 1.00 mmol) of 1-bromobutane was added into a 
mixture of 90.0 mg (0.16 mmol) of compound 2.27 in 2 mL of acetonitrile and 0.17 g 
(1.60 mmol) of Na2CO3. The reaction mixture was sealed under nitrogen atmosphere and 
stirred at 80 oC for ~ 30 h. The reaction mixture was cooled to room temperature and 
filtered. The filtrate was concentrated under diminished pressure. The crude product was 
used to the next step without further purification. 
 61   
S
N
ON  
7-(N-Butyl-N-pentadecylamino)-3H-phenothiazin-3-one (2.9). 0.48 mL (0.48 mmol) 
of 1 M BBr3 in CH2Cl2 was added dropwise into the solution of 100 mg (~ 0.16 mmol) of 
crude 2.29 in 2 mL of CH2Cl2 at _78 oC. The reaction mixture was stirred overnight at 
room temperature and was quenched with 10 mL of water. The crude product was 
extracted with two 10-mL portions of ethyl acetate. The combined organic layer was 
washed with 20 mL of brine, dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The resulting violet solid was purified on a silica gel column (7 x 2 
cm). Elution with 3:7 ethyl acetate_hexanes afforded 2.9 as a violet solid: yield 20 mg 
(25%); silica gel TLC Rf  0.50 (1:4 ethyl acetate_hexanes); 1H NMR (CDCl3) δ 0.88 (t, 
3H, J = 6.6 Hz), 1.00 (t, 3H, J = 7.2 Hz), 1.26-1.43 (m, 26H), 1.62-1.64 (m, 4H), 3.36-
3.41 (m, 4H), 6.55 (d, 1H, J = 2.4 Hz), 6.71 (s, 1H), 6.79-6.85 (m, 2H), 7.57 (d, 1H, J = 
9.6 Hz) and 7.68 (d, 1H, J = 9.2 Hz); 13C NMR (CDCl3) δ 14.3, 22.8, 27.1, 27.5, 29.50, 
29.53, 29.6, 29.7, 29.77, 29.79, 29.81, 29.83, 32.1, 51.5, 104.8, 113.3, 118.7, 128.7, 
131.0, 132.4, 134.9, 136.0, 139.6, 140.0, 150.0 and 182.4; mass spectrum (APCI), m/z 
495.3330 (M + H)+ (C31H47N2OS requires m/z 495.3331). 
S
N
N OMe
O O
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tert-Butyl 3-(N,N-Dihexadecylamino)-7-methoxy-10H-phenothiazin-10-carboxylate 
(2.26). 1.40 mL (4.35 mmol) of 1-iodohexadecane in 2 mL of acetonitrile was added into 
a mixture of  0.50 g (~ 1.16 mmol) of crude 2.22 in 2 mL of acetonitrile and 1.50 g (14.5 
mmol) of Na2CO3. The reaction mixture was sealed under nitrogen atmosphere and 
stirred at 80 oC for ~ 48 h. The reaction mixture was cooled to room temperature and 
filtered. The filtrate was concentrated under diminished pressure and the crude was used 
in the next reaction without further purification. 
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7-(N,N-Dihexadecylamino)-3H-phenothiazin-3-one (2.10). 50.0 µL (0.05 mmol) of 1 
M BBr3 in CH2Cl2 was added dropwise into the solution of 20.0 mg (0.03 mmol) of 
compound 2.26 in 2 mL of CH2Cl2 at _78 oC. The reaction mixture was stirred overnight 
at room temperature and was quenched with 10 mL of water. The crude product was 
extracted with two 10-mL portions of ethyl acetate. The combined organic layer was 
washed with 20 mL of brine, dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The resulting violet solid was purified on a silica gel column (10 x 2 
cm). Elution with 1:4 ethyl acetate_hexanes afforded 2.10 as a violet solid: yield 8 mg 
(50%); silica gel TLC Rf  0.50 (1:4 ethyl acetate_hexanes); 1H NMR (CDCl3) δ 0.87 (t, 
6H, J = 6.2 Hz), 1.26-1.35 (m, 52H), 1.64 (br s, 4H), 3.38 (t, 4H, J = 7.4 Hz), 6.54 (br s, 
1H), 6.71 (br s,1H), 6.78-6.86 (m, 2H), 7.60 (d, 1H, J = 9.0 Hz) and 7.67 (d, 1H, J = 8.8 
Hz); 13C NMR (CDCl3) δ 14.1, 14.2, 21.0, 22.7, 27.0, 27.4, 29.3, 29.4, 29.5, 29.60, 29.63, 
29.67, 31.9, 51.5, 60.4,104.8, 113.60, 113.62, 118.1,131.7, 134.7, 136.1, 139.4, 139.5, 
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150.1, 169.2 and 171.1; mass spectrum (APCI), m/z 677.5367 (M + H)+ (C44H72N2OS 
requires m/z 677.5365).                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64   
CHAPTER 3 
 
3. SYNTHESIS OF FLUORESCENT DIPEPTIDOMIMETICS AND THEIR 
RIBOSOMAL INCORPORATION INTO GREEN FLUORESCENT PROTEIN 
3.1 Introduction 
    Green fluorescent protein (GFP) exemplifies a family of chromoproteins consisting of 
about 220-240 amino acid residues (25 kDa).94 GFP was first isolated by the Shimomura 
group from the jellyfish Aequorea victoria in 1962.95 Over the next 30 years, GFP was 
mainly limited to studies of luminescent marine creatures.94 The crucial breakthrough 
came after its cloning in 1992 by Prasher et al.96 and its utilization as fluorescent tag for 
gene expression in 1994 by Chalfie et al.97 Aequorea victoria GFP consists of 238 amino 
acid residues, which fold into a β-barrel, formed by 11β-sheets that accommodate an 
internal distorted helix. The chromophore of GFP, also reported by Shimomura, is a 4-(p-
hydroxybenzylidene)imidazolidin-5-one moiety, which forms by a posttranslational 
cyclization and oxidation of the polypeptide backbone, involving the Ser65-Tyr66-Gly67 
residues.98 This results in an extended conjugated system capable of absorbing and 
emitting visible light (Scheme 3.1). 
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Scheme 3.1. Proposed mechanism of formation of GFP chromophore.99-101 The reactive 
nitrogen and carbonyl groups are highlighted in blue. The final structure of the 
chromophore is shown in green. 
 
 
HN
N
H
O
O
OH
Try66
Gly67
N
H
NH+
O-
O
O
OH
HO
HN
N
H
N
OH
O
O
OH
HO
H
N
-H+, +H+
dehydration
-H+
+H+ O2
O
N
H
OH
Ser65
cyclization
N
N
O
O
HO
NH
OH
N
N
O
O
HO
NH
OH
N
N
O
O
O
NH
OH
  
The amino acid at position 65 can vary but Tyr66 and Gly67 are conserved for all 
proteins within GFP family.102 The GFP chromophore is located in the center of the β-
barrel and therefore is well shielded from solvent molecules. Additionally, the β-barrel is 
stabilized by multiple non-covalent interactions, which make it highly stable with respect 
to its thermal and chemical properties, as well as susceptibility to proteolysis.94 
    The GFP chromophore has absorption peaks at 395 and 475 nm, usually assigned to 
the neutral and anionic forms of the chromophore, respectively (Scheme 3.1), and an 
emission peak at 509 nm with a high fluorescence quantum yield (0.79).103 There have 
been extensive efforts to improve or alter the spectral properties of GFP. For example, 
Schultz and coworkers have replaced Tyr66 by phenylalanine analogues using site-
directed mutagenesis (Figure 3.1).104 Numerous reports have described the study and 
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spectral properties of novel fluorescent proteins and their chromophores.105,106 In 
comparison, there has been no report of the incorporation of a preformed fluorophore into 
a protein backbone by in vitro protein translation. 
NH2
H2N
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OCH3
H2N
COOH
I
H2N
COOH
Br
H2N
COOH
λmax
abs
λmax
em
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381 nm
438 nm
435 nm
498 nm  
Figure 3.1. Structures of unnatural Phe analogues substituted for Tyr66 of GFP and the 
photophysical properties of their corresponding GFP.104 
 
    Peptidomimetics are small molecules, designed to mimic a natural peptide or protein. 
They often exhibit very similar biological effects as the parent protein or peptide, or 
support some new effect. Oxazole and thiazole based peptidomimetics are widespread 
among bioactive molecules. For example, microcin B17, a bacterial DNA gyrase 
inhibitor,107 and goadsporin, a promoter of secondary metabolism and morphogenesis in 
Streptomycetes, contain both oxazole and thiazole moieties. Thiostrepton, an inhibitor of 
bacterial ribosome function,108 contains multiple thiazole moieties. Given the extensive 
occurrence of oxazole and thiazole moieties in natural products, there has been 
considerable interest in the use of such precursors in preparing bioactive molecules and 
peptidomimetic structures synthetically.109-112 At present, we report the synthesis and 
incorporation of novel fluorescent oxazole and thiazole-based dipeptide analogues, which 
are also reminiscent of the fluorophores formed by naturally occurring fluorescent 
proteins, into GFP. The structures of the dipeptidomimetic analogues are shown in Figure 
3.2.113                  
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Figure 3.2.  Chemical structures of the dipeptidomimetic analogues synthesized. 
3.2 Results 
    The retrosynthetic analysis of the dipeptidomimetic analogues is shown in Scheme 
3.2.114 Double C, N acylation of glycine affords α-amido-β-ketoesters, which were then 
Scheme 3.2. Retrosynthetic analysis for the syntheses of the dipeptidomimetic analogues.  
X
N
R2
COOR3
R1
N
H O
OR3
O R2
R1
O
H2N
OH
O  
transformed to oxazoles and thiazoles.  The syntheses of the pdCpA derivatives of the 
dipeptidomimetic analogues are shown in Schemes 3.3-3.8. Commercially available 
glycine methyl ester hydrochloride was treated with benzophenone imine to obtain fully 
protected glycine 3.7115 which was condensed with various p-substituted benzoyl 
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chlorides in the presence of 1 M NaHMDS in THF. Subsequent hydrolysis of the imine 
with conc. HCl afforded corresponding α-amino-β-ketoesters as crude products, which 
were condensed directly with Fmoc-gly-N-hydroxysuccinimide to obtain α-amido-β-
ketoester intermediates in varying yields.114 Cyclodehydration of the α-amido-β-
ketoesters using triphenylphosphine in the presence of iodine and triethylamine in 
anhydrous dichloromethane at room temperature afforded the oxazoles.116 The 
corresponding thiazoles were obtained by treating the α-amido-β-ketoesters with 
Lawesson’s reagent. Subsequent removal of the Fmoc group with piperidine followed by 
treatment with pentenoyloxy succinimide117 yielded the pentenoyl protected compounds, 
which were then saponified and activated as cyanomethyl esters.118 The cyanomethyl 
esters were then used for the acylation of the dinucleotide pdCpA.119 A mixture of the 
cyanomethyl esters and tris(tetrabutylammonium) salt of pdCpA in 9:1 DMF_Et3N was 
sonicated for 4 h and purified by reversed phase HPLC using a semi-preparative C18 
column, which provided the corresponding pdCpA derivatives. 
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Scheme 3.3. Synthetic route for the preparation of the pdCpA derivative of 
dipeptidomimetic analogue 3.1.  
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Scheme 3.4. Synthetic route for the preparation of the pdCpA derivative of 
dipeptidomimetic analogue 3.2.   
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Scheme 3.5. Synthetic route for the preparation of the pdCpA derivative of 
dipeptidomimetic analogue 3.3. 
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Scheme 3.6. Synthetic route for the preparation of the pdCpA derivative of 
dipeptidomimetic analogue 3.4. 
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Scheme 3.7. Synthetic route for the preparation of the pdCpA derivative of 
dipeptidomimetic analogue 3.5. 
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Scheme 3.8. Synthetic route for the preparation of the pdCpA derivative of 
dipeptidomimetic analogue 3.6. 
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    The photophysical properties of the dipeptidomimetic analogues were characterized by 
measuring the molar absorptivities, quantum yields, emission maxima and absorption 
maxima of the corresponding N-pentenoyl methyl ester derivatives in methanol (Table 
3.1). The absorbance and emission maxima of the analogues span the range from 285 to 
352 nm and 365 to 490 nm, respectively. All the compounds displayed maximum 
fluorescence intensity when they were excited at their respective absorption peak 
wavelengths. Compounds 3.1 and 3.2 were strongly fluorescent with absorption peaks at 
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~300 nm and emission peaks at ~391 and ~420 nm, respectively. The UV absorption and 
fluorescence emissions of 3.3 and 3.4 were the most red-shifted compared to all other 
analogues. The emission peak wavelength of 3.4 (~490 nm) was closest to the emission 
peak wavelength of wild type GFP (~509 nm) with a large Stokes shift (~138 nm). 
Nonetheless, 3.4 was a poor fluorescent probe since it had very low quantum yield (0.04). 
Compound 3.3 was the best fluorescent probe among all the analogues. Because it had 
high quantum yield (0.62), high molar absorptivity (20000 M-1 cm-1), large Stokes shift 
(108 nm) and it emitted in the blue region (460 nm) of the spectrum. Compounds 3.5 and 
3.6 exhibited very poor fluorescence properties either in terms of shorter wavelengths of 
emission or lower quantum yields or both. 
Table 3.1. Photophysical properties of the dipeptidomimetic analogues in MeOH.  
Compounds λex, max (nm) λem, max (nm) ε (M-1 cm-1) ɸF120 
3.1 296 391 17600 0.90 
3.2 300 420 11000 0.23 
3.3 352 460 20000 0.62 
3.4 352 490 7500 0.04 
3.5 285 365 13800 0.26 
3.6 290 390 9530 0.01 
 
    The activated pdCpA derivatives were ligated to an abbreviated tRNACUA-COH 
transcript using T4 RNA ligase (Scheme 3.9), affording the respective misacylated 
suppressor tRNA transcripts. The N-pentenoyl protecting group was removed by 
treatment with aqueous iodine.117  Removal of the protecting group was done immediately 
prior to the use of misacylated tRNAs in protein synthesis.  
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Scheme 3.9. Ligation of the pdCpA derivatives with tRNACUA-COH.  
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Figure 3.3. Preparation of dipeptidomimetic-tRNACUAs. Lane 1, nonacylated abbreviated 
tRNACUA; lane 2, tRNACUA ligated with 3.1; lane 3, tRNACUA ligated with 3.2; lane 4, 
tRNACUA ligated with 3.3; lane 5, tRNACUA ligated with 3.4; lane 6, tRNACUA ligated 
with 3.5; lane 7, tRNACUA ligated with 3.6; lane 7, nonacylated abbreviated tRNACUA. 
     The deprotected tRNAs were used in a cell-free coupled transcription_translation 
system containing an S-30 fraction prepared from Escherichia coli, programmed with a 
GFP analogue construct having a TAG codon at position 66 (pETGFP66 plasmid).113 The 
suppression efficiencies were expressed relative to the wild-type GFP synthesis from the 
wild-type mRNA. As a negative control, wild-type GFP synthesis from the modified 
mRNA in the presence of nonacylated tRNACUA was measured for each experiment. The 
amounts of GFP produced were quantified with a phosphoimager, which monitored the 
incorporation of 35S-methionine into proteins. S-30 preparations having the modified 
ribosomes from clone 010326R660 produced full length GFP in ~6.5% yield relative to 
wild-type GFP synthesis in case of 3.1, while in case of 3.2 the suppression yield was 
 77   
~3.5% relative to wild-type GFP synthesis (Figure 3.4).113 The suppression yields for 
compounds 3.3-3.6 were ~12%, 11%, 5% and 5%, respectively (Table 3.2). 
                                                       wt           no          3.1           3.2          
                                                                                  100      0.3±0.2   6.4±0.5   3.5±0.4    % suppression   
Figure 3.4. Autoradiogram of a 15% SDS-polyacrylamide gel depicting the 
incorporation of dipeptidomimetic analogues 3.1 and 3.2 into position 66 of GFP. 
Translation of protein from a wild-type (lane 1) and modified GFP mRNA having a 
UAG codon in position 66 (lanes 2-4) by the use of an S-30 system prepared from 
ribosomal clone 010326R6 in the presence of different suppressor tRNAs. Lane 1, wild-
type GFP expression; lane 2, modified GFP mRNA in the presence of an abbreviated 
suppressor tRNACUA-COH; lane 3, tRNACUA activated with 3.1; lane 4, tRNACUA 
activated with 3.2. Phosphorimager analysis was performed using an Amersham 
Biosciences Storm 820 equipped with ImageQuant version 5.2 software from Molecular 
Dynamics. 
 
Table 3.2. Suppression yields for compounds 3.3-3.6. (Experiment was done by Dr. 
Larisa dedkova) 
 
 3.3 3.4 3.5 3.6 
Suppression yield 12% 11% 5% 5% 
 
    An increased concentration (0.6 ‒ 1.0 μg/μL) of the activated suppressor tRNACUA was 
crucial for effective translation. This concentration was quite excessive compared to the 
suppressor tRNACUA concentration used for the expression of α-amino acids (0.1 ‒ 0.2 
μg/μL). At lower concentrations of the aminoacyl-tRNACUA minimal suppression was 
observed.113  
    The GFP analogues having 3.1 and 3.2 at position 66 were prepared at larger scale and 
purified to study the fluorescence intensity of 3.1 and 3.2 in the protein. The purified 
proteins containing 3.1 and 3.2 were excited at 305 and 302 nm, respectively. The GFP 
analogue containing 3.1 exhibited a fluorescence emission maximum at ~375 nm whereas 
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the protein carrying 3.2 had an emission maximum at ~403 nm (Figure 3.5).113 In 
addition, the fluorescence intensities of both the GFP analogues were compared with 
wild-type GFP. The fluorescence intensities of the modified GFP analogues were 
significantly greater than wild-type GFP at the same protein concentration. 
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Figure 3.5. Fluorescence emission spectra of three different GFP samples. The red trace 
is of GFP having dipeptidomimetic analogue 3.1 at position 66; excitation at 305 nm. 
The blue trace is of GFP having dipeptidomimetic analogue 3.2 at position 66; excitation 
was at 302 nm. The green trace is of wild-type GFP sample; excitation was at 395 nm. 
The fluorescence emission spectra were recorded using ~20 nM GFP concentration in 25 
mM Tris-HCl, pH 7.4, containing 0.5 M NaCl. 
3.3 Discussion 
    The synthesis of 1, 3-oxazoles and 1, 3-thiazoles has been the focus of many research 
groups due to their presence in numerous natural products.110-112 Nature synthesizes 
oxazoles through cyclodehydration-oxidation of acylserine derivatives. Most of the 
synthetic routes for oxazoles also follow this scheme. A versatile synthesis of 1, 3-
oxazoles was reported by Dr. Robinson in 1909121 and Dr. Gabriel in 1910122, 
respectively; it is known as the Robinson-Gabriel oxazole synthesis. According to this 
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method oxazoles are obtained by the cyclodehydration of α-acylaminoketones, esters or 
amides. The oxazole synthesis described in this thesis is a versatile extension of the 
Robinson-Gabriel method. The α-amido-β-ketoesters were directly cyclized using a 
dehydrating mixture of two equivalents of triphenylphosphine, iodine and 
triethylamine.109 The reaction was complete in 15 minutes at room temperature. Several 
plausible mechanisms can be envisioned for the conversion. Wipf et al. proposed two 
mechanisms which are shown in Scheme 3.10.109 In the absence of any base 
(triethylamine here) no reaction occurs at room temperature; accordingly an initial 
enolization of 3.32 was proposed. The enol is trapped by highly electrophilic Ph3PI2 to 
form 3.33. In the next step, an intramolecular addition of the amide onto the 
vinylphosphonium species can lead to product formation. The nucleophilic attack will be 
especially favored if the R3 is electron withdrawing. However, this mechanism can be 
questioned for a number of reasons. First, the ring closure is disfavored because it is a 5-
endo-trig type123,124, second, when R3 = CH3, an increase rather than a decrease in yield 
of 3.35 is observed. So, an alternative mechanism via acylimino carbene 3.36 was 
proposed by Wipf et al. This mechanism might be more plausible because ring closure of 
3.36 to oxazoles was already observed.125     
    Similar to 1, 3-oxazoles, there are number of methods for the synthesis of 1, 3-
thiazoles, the most common of them being the Hantzsch synthesis where suitably 
substituted α-haloketones and thioamides are condensed.126 In this report, the thiazoles 
were obtained by the cyclization of α-amido-β-ketoesters with Lawessons’s reagent. This 
method was followed since α-amido-β-ketoester was a common intermediate for both 
oxazole and thiazole synthesis, which simplified the entire process. 
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Scheme 3.10. Proposed mechanism for the cyclization of α-amido-β-ketoesters.                
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     Aequorea victoria GFP chromophore contains a Tyr moiety (Scheme 3.1). The 
phenolic OH group of the Tyr moiety is particularly important for the photophysical 
properties of GFP. There has been an extensive structure-activity study on the 
fluorophore of GFP.105 In addition, several mutant GFPs containing Phe analogues with 
different para-substituents, in place of Tyr66, were prepared by Schultz and coworkers.104 
All these studies indicate that the wavelengths for both absorbance and emission peaks of 
the mutant GFPs increased with an increase in the electron-donating ability of the aryl 
substituents. In order to see the effect of the substituents on the photophysical properties 
of the peptidomimetic analogues that I prepared, several analogues containing either 
electron donating (NMe2, OMe) or electron withdrawing (CN) substituents were 
synthesized. An analogue having phenolic OH group was omitted in order to avoid 
complicated synthetic steps as well as the possible multiple charge state of the 
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chromophore under the assay conditions. The wavelengths of absorbance and emission 
peaks for both oxazoles and thiazoles follow the order NMe2 > OMe > CN, which is in 
accordance with earlier studies.104 The NMe2 is the most electron donating substituent, 
and exhibited the maximum red shift of the absorption and emission peaks. Compounds 
3.3 and 3.4 had absorption peaks at ~352 nm and the emission peaks at ~460 and 490 nm 
in methanol, respectively (Table 3.1). In comparison compounds 3.5 and 3.6 exhibited 
the shortest absorption and emission peaks. In all the cases, the emission peaks of the 
thiazoles were ~20-30 nm red shifted compared to the corresponding oxazoles. 
    Hecht and coworkers have been trying to incorporate unnatural amino acids into 
proteins by modified ribosomes.57-59 So far, a single unnatural amino acid was 
incorporated into protein by the suppression of a single amber stop codon. In 2015 there 
was a significant improvement in this method when our group incorporated dipeptides 
and a dipeptidomimetic analogue, which can be seen as two amino acids tied together, 
into proteins by the suppression of a single stop codon.60 The S-30 system contained the 
modified ribosomes, which had altered peptidyltransferase centers. The modified 
ribosomes were able to recognize dipeptides and dipeptide analogues in addition to α-L-
amino acids.60 A dipeptidyl puromycin derivative (1.2, Figure 1.15) was used to select 
the modified ribosomes. Recognition of the dipeptidomimetic analogues by these 
modified ribosomes is presumably due to the fact that the distance between the amine and 
carboxylate groups in the dipeptidomimetics is similar to the distance between the free 
amine and carboxylate groups of a dipeptide. When these S-30 systems were employed 
for the in vitro translation experiments, they produced full length GFP containing 3.1-3.6 
in yields ranging from ~3.5% to ~12%. Additionally, the mutant GFPs containing 3.1 and 
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3.2 were scaled up to study the fluorescence of the dipeptidomimetic analogues in 
protein. It was observed that the mutant GFP analogue containing 3.1 had ~10-fold 
higher fluorescence intensity compared to wild-type GFP at the same protein 
concentration, while the GFP analogue containing 3.2 had ~7-fold higher fluorescence 
intensity.113 Thus these fluorophores are sensitive to their environment, a property, which 
should be applicable to many applications. 
3.4. Experimental  
    All experiments requiring anhydrous conditions were conducted in flame-dried 
glassware fitted with rubber septa under a positive pressure of dry argon. Analytical thin 
layer chromatography was performed using glass plates precoated with silica gel (0.25 
mm, 60 pore size, 230-400 mesh, Silicycle) impregnated with a fluorescent indicator (254 
nm). TLC plates were visualized by exposure to ultraviolet light (UV). Flash column 
chromatography was performed employing silica gel (60 Å pore size, 40-63 μm, standard 
grade Silicycle silica gel). An acetone cooling bath was adjusted to the appropriate 
temperature by the addition of small portions of dry ice. 
    1H NMR and 13C NMR spectra were recorded on Varian INOVA 400 (400 MHz) 
spectrometer at 25 oC. Proton chemical shifts are expressed in parts per million (ppm, δ 
scale). Splitting patterns are indicated as follows; s, singlet; br s, broad singlet; d, doublet; 
dd, doublet of doublets; t, triplet; q, quartet; m, multiplet. High resolution mass spectra 
were obtained at the Arizona State University CLAS High Resolution Mass Spectrometry 
Facility or at the Michigan State University Mass Spectrometry Facility. HPLC 
purification was conducted with a Waters 600 pump coupled with a Varian-ProStar 340 
detector and a Grace Econosil C18 column (250 × 10 mm, 5 μm). The tetra(n-
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butyl)ammonium (TBA) salt of pdCpA was prepared using Dowex 50W×8, 200-400 
mesh activated in its TBA form. Reagents were purchased from Aldrich Chemical Co., 
Sigma Chemical Co., Combi Blocks or Chem Impex International and were used without 
further purification. THF was distilled under argon from benzophenone ketyl and CH2Cl2 
was distilled under argon from calcium hydride.  
    Tris, acrylamide, bis-acrylamide, urea, ammonium persulfate, TEMED, dihydrofolic 
acid, glycerol, ampicillin, pyruvate kinase, lysozyme, erythromycin, isopropyl-β-D-
thiogalactopyranoside (IPTG), dithiothreitol (DTT) and 2-mercaptoethanol were 
purchased from Sigma Chemicals (St. Louis, MO). 35S-Methionine (10 μCi/μL) was 
purchased from Amersham (Pitscataway, NJ). BL-21-(DE-3) competent cells and T4 
RNA ligase were from Promega (Madison, WI). Plasmid MaxiKit (Life Science 
Products, Inc., Frederick, CO) and GenElute™HP plasmid miniprep kit (Sigma) were 
used for plasmid purification. 
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Methyl 2-(Diphenylmethyleneamino)acetate (3.7). To a stirred suspension containing 
5.00 g (39.9 mmol) of glycine methyl ester hydrochloride in 20 mL of anhydrous 
CH2Cl2 was added dropwise 6.70 mL (7.20 g, 39.9 mmol) of benzophenone imine. The 
reaction mixture was stirred at 25 oC for 24 h under an argon atmosphere. The reaction 
mixture was filtered and concentrated under diminished pressure. The crude product was 
crystallized from ether–hexanes to afford 3.7 as colorless needles: yield 8.20 g (81%); 
silica gel TLC Rf 0.22 (1:9 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 3.73 (s, 3H), 
4.21 (s, 2H), 7.15-7.18 (m, 2H), 7.30-7.45 (m, 6H) and 7.63-7.66 (m, 2H); 13C NMR 
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(CDCl3) δ 52.0, 55.6, 127.6, 128.1, 128.69, 128.75, 128.83, 130.5, 135.9, 139.2, 171.1 
and 171.9; mass spectrum (APCI), m/z 254.1182 (M + H)+ (C16H16NO2 requires m/z 
254.1181). 
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Methyl 2-(2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)acetamido)-3-(4-
methoxyphenyl)-3-oxopropanoate (3.9). A solution of 0.50 g (2.00 mmol) of 3.7 in 5 
mL of anhydrous THF was cooled to _78 oC under an argon atmosphere and 2.00 mL 
(2.00 mmol) of 1 M sodium bis(trimethylsilyl)amide in THF was added dropwise while 
maintaining the temperature at _78 oC. After 30 min, the resulting yellow solution was 
added via cannula to a stirred solution of 0.34 g (2.00 mmol) of 4-methoxybenzoyl 
chloride in 3 mL of anhydrous THF at _78 oC. The reaction mixture was stirred at _78 oC 
for 2 h. The yellow reaction mixture was acidified with concentrated HCl to pH ~2 and 
was concentrated under diminished pressure. The crude product (3.8) was utilized for the 
next reaction without further purification.  
    To a solution of the crude product in 10 mL of anhydrous THF at 0 oC was added 0.79 
g (2.00 mmol) of Fmoc-gly-N-hydroxysuccinimide ester followed by the dropwise 
addition of 0.22 mL (0.20 g, 2.00 mmol) N-methylmorpholine. The yellow reaction 
mixture was stirred at 25 oC for 2 h and then concentrated under diminished pressure. The 
crude product was purified on a silica gel column (15 × 2 cm). Elution with 1:1 ethyl 
acetate−hexanes afforded 3.9 as a colorless oil: yield 0.67 g (67%); silica gel TLC Rf 0.29 
(3:2 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 3.69 (s, 3H), 3.86 (s, 3H), 4.06 (br s, 
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2H), 4.23 (d, 1H, J = 6.8 Hz), 4.40 (d, 2H, J = 7.2 Hz), 5.68 (br s, 1H), 6.18 (d, 1H, J = 
7.6 Hz), 6.94 (d, 2H, J = 8.8 Hz), 7.29 (t, 2H, J = 7.4 Hz), 7.38 (t, 2H, J = 7.4 Hz), 7.54 
(d, 1H, J = 6.8 Hz), 7.60 (d, 2H, J = 7.2 Hz), 7.75 (d, 2H, J = 7.6 Hz) and 8.09 (d, 2H, J = 
8.8 Hz); 13C NMR (CDCl3) δ 44.3, 47.2, 53.4, 55.7, 57.7, 67.4, 114.2, 120.0, 125.2, 
126.8, 127.2, 127.8, 132.2, 141.3, 143.9, 156.6, 164.9, 167.2, 169.0 and 189.1; mass 
spectrum (APCI), m/z 503.1816 (M + H)+ (C28H27N2O7 requires m/z 503.1818). 
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Methyl 2-((((9H-Fluoren-9-yl)methoxy)carbonylamino)methyl)-4-(4-
methoxyphenyl)oxazole-5-carboxylate (3.10). To a stirred solution of 0.17 g (0.80 
mmol) of triphenylphosphine and 0.20 g (0.80 mmol) of iodine in 10 mL of anhydrous 
CH2Cl2 was added 0.11 mL (83.0 mg, 0.80 mmol) of triethylamine. The dark yellow 
solution was stirred for 5 min and 0.20 g (0.40 mmol) of 3.9 dissolved in 5 mL anhydrous 
CH2Cl2 was added dropwise. The reaction mixture was stirred for 30 min at 25 oC under 
an argon atmosphere and was then concentrated under diminished pressure. The residue 
was purified on a silica gel column (15 × 2 cm). Elution with 3:2 ethyl acetate−hexanes 
afforded 3.10 as a colorless solid: yield 0.15 g (78%); silica gel TLC Rf  0.45 (3:2 ethyl 
acetate−hexanes); 
1H NMR (CDCl3) δ 3.85 (s, 3H), 3.92 (s, 3H), 4.23 (t, 1H, J = 7.0 Hz), 
4.45 (d, 2H, J = 6.8 Hz), 4.59 (d, 2H, J = 5.6 Hz), 5.63 (br s, 1H), 6.96 (d, 2H, J = 8.8 
Hz), 7.28 (t, 2H, J = 7.6 Hz), 7.38 (t, 2H, J = 7.4 Hz), 7.59 (d, 2H, J = 7.6 Hz), 7.75 (d, 
2H, J = 7.2 Hz) and 8.02 (d, 2H, J = 9.2 Hz); 13C NMR (CDCl3) δ 38.4, 47.2, 52.4, 55.5, 
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67.4, 114.0, 119.1, 120.1, 125.1, 125.4, 127.2, 127.8, 130.2, 141.4, 143.8, 156.3, 156.4, 
158.5, 161.4 and 162.6; mass spectrum (APCI), m/z 485.1722 (M + H)+ (C28H25N2O6 
requires m/z 485.1713). 
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Methyl 4-(4-Methoxyphenyl)-2-(pent-4-enamidomethyl)oxazole-5-carboxylate (3.1). 
To a stirred solution of 0.15 g (0.31 mmol) of 3.10 in 4 mL of anhydrous CH2Cl2 was 
added dropwise 31.0 μL (27.0 mg, 0.31 mmol) of piperidine. The reaction mixture was 
stirred at 25 oC under an argon atmosphere for 2 h and was then concentrated under 
diminished pressure. The residue was dissolved in 5 mL of anhydrous THF and 0.61 g 
(3.10 mmol) of 4-pentenoyloxysuccinimide was added followed by 66.0 mg (0.62 
mmol) of Na2CO3. The reaction mixture was stirred at room temperature for 3 h under 
an argon atmosphere and was then concentrated under diminished pressure. The residue 
was purified on a silica gel column (7 × 2 cm). Elution with 7:3 ethyl acetate−hexanes 
afforded 3.1 as a pale yellow solid: yield 45.0 mg (42% over two steps); silica gel TLC 
Rf 0.19 (7:3 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 2.33-2.42 (m, 4H), 3.84 (s, 3H), 
3.90 (s, 3H), 4.62 (d, 2H, J = 5.6 Hz), 4.97-5.08 (m, 2H), 5.76-5.85 (m, 1H), 6.43 (br s, 
1H), 6.95 (d, 2H, J = 9.2 Hz) and 8.00 (d, 2H, J = 8.8 Hz); 13C NMR (CDCl3) δ 29.4, 
35.6, 36.6, 52.3, 55.5, 114.0, 115.8, 119.1, 125.3, 130.2, 136.9, 156.4, 158.6, 161.4, 
162.5 and 172.5; mass spectrum (APCI), m/z 345.1452 (M + H)+ (C18H21N2O5 requires 
m/z 345.1450). 
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Cyanomethyl 4-(4-Methoxyphenyl)-2-(pent-4-enamidomethyl)oxazole-5-
carboxylate (3.11). To a stirred solution of 15.0 mg (0.04 mmol) of 3.1 in 0.40 mL of 
3:1 THF_water was added 0.13 mL of 1 N LiOH. The reaction mixture was stirred at 25 
oC for 2 h. The yellow reaction mixture was diluted with MeOH, dried over anhydrous 
Na2SO4 and was concentrated under diminished pressure. The crude product was 
dissolved in 2 mL of anhydrous DMF and 27.0 mg (0.32 mmol) of NaHCO3 was added, 
followed by 13.0 μL (15.0 mg, 0.21 mmol) of ClCH2CN. The reaction mixture was 
stirred at 25 oC for 3 h under an argon atmosphere. The reaction mixture was 
concentrated under diminished pressure and the residue was purified on a silica gel 
column (7 × 1 cm). Elution with 2.5% methanol in dichloromethane afforded 3.11 as a 
pale yellow solid: yield 5.5 mg (37%); silica gel TLC Rf 0.74 (ethyl acetate); 1H NMR 
(CDCl3) δ 2.39-2.44 (m, 4H), 3.87 (s, 3H), 4.65 (d, 2H, J = 5.6 Hz), 4.94 (s, 2H), 5.00-
5.10 (m, 2H), 5.80-5.87 (m, 1H), 6.25 (br s, 1H), 6.99 (d, 2H, J = 8.8 Hz) and 8.01 (d, 
2H, J = 8.8 Hz); 13C NMR (CDCl3) δ 29.4, 31.1, 35.6, 36.7, 48.8, 55.6, 114.2, 116.0, 
118.5, 123.5, 130.4, 136.8, 158.3, 158.9, 160.6, 162.0 and 172.5; mass spectrum (APCI), 
m/z 370.1402 (M + H)+ (C19H20N3O5 requires m/z 370.1403). 
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4-(4-Methoxyphenyl)-2-(pent-4-enamidomethyl)oxazole-5-carboxylate pdCpA 
(3.12). A solution containing 6.0 mg (16 μmol) of cyanomethyl ester 3.11 and 5.3 mg 
(4.0 μmol) of the tris(tetrabutylammonium) salt of pdCpA in 100 μL of 9:1 DMF–Et3N 
was subjected to sonication at room temperature for 4 h. The reaction mixture was 
diluted with 0.5 mL of 50 mM ammonium acetate, pH 4.5 and centrifuged. The 
supernatant was purified by C18 reversed phase HPLC (250 x 10 mm) using a gradient of 
1% 65% acetonitrile in 50 mM ammonium acetate, pH 4.5, over a period of 45 min. 
The fraction eluting at 19 min was collected and lyophilized to afford 3.12 as a colorless 
solid: yield 2.3 mg (60%); mass spectrum (ESI), m/z 947.2159 (M − H)− 
(C36H41N10O17P2 requires m/z 947.2126). 
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Methyl 2-((((9H-Fluoren-9-yl)methoxy)carbonylamino)methyl)-4-(4-
methoxyphenyl)thiazole-5-carboxylate (3.13). To a stirred solution of 0.22 g (0.44 
mmol) of 3.9 in 5 mL of anhydrous THF was added 0.36 g (0.88 mmol) of the 
Lawesson’s reagent. The reaction mixture was heated to reflux under an argon 
atmosphere for 1 h. The yellow reaction mixture was diluted with 20 mL of saturated 
NaHCO3 solution. The aqueous layer was extracted with two 25-mL portions of ethyl 
acetate. The combined organic layer was dried over anhydrous MgSO4 and was 
concentrated under diminished pressure. The residue was purified on a silica gel column 
(15 × 2 cm). Elution with 3:2 ethyl acetate−hexanes afforded 3.13 as a colorless solid: 
yield 0.18 g (80%); silica gel TLC Rf  0.48 (7:3 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 3.84 (s, 3H), 3.85 (s, 3H), 4.23 (t, 1H, J = 6.6 Hz), 4.49 (d, 2H, J = 6.8 Hz), 
4.67 (d, 2H, J = 6.0 Hz), 5.62 (br s, 1H), 6.94 (d, 2H, J = 7.6 Hz), 7.29 (t, 2H, J = 7.2 
Hz), 7.37 (t, 2H, J = 7.2 Hz), 7.51 (d, 2H, J = 8.4 Hz), 7.58 (d, 2H, J = 7.2 Hz) and 7.75 
(d, 2H, J = 7.2 Hz); 13C NMR (CDCl3) δ 42.8, 47.3, 52.4, 55.5, 67.2, 113.8, 120.1, 
122.2, 125.1, 127.2, 127.9, 131.4, 138.9, 141.4, 143.8, 148.2, 156.4, 160.6, 162.5 and 
165.9; mass spectrum (APCI), m/z 501.1468 (M + H)+ (C28H25N2O5S requires m/z 
501.1484). 
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Methyl 4-(4-Methoxyphenyl)-2-(pent-4-enamidomethyl)thiazole-5-carboxylate 
(3.2). To a stirred solution of 0.17 g (0.34 mmol) of 3.13 in 4 mL of anhydrous CH2Cl2 
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was added dropwise 67.0 μL (58.0 mg, 0.68 mmol) of piperidine. The reaction mixture 
was stirred at 25 oC under an argon atmosphere for 3 h and was concentrated under 
diminished pressure. The residue was dissolved in 5 mL of anhydrous THF and 0.13 g 
(0.66 mmol) of 4-pentenoyloxysuccinimide was added, followed by 47.0 mg (0.44 
mmol) of Na2CO3. The reaction mixture was stirred at room temperature for 3 h under 
an argon atmosphere and was then concentrated under diminished pressure. The residue 
was purified on a silica gel column (7 × 2 cm). Elution with 7:3 ethyl acetate−hexanes 
afforded 3.2 as a pale yellow solid: yield 55.0 mg (45% over two steps); silica gel TLC 
Rf 0.19 (7:3 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 2.32-2.41 (m, 4H), 3.81 (s, 3H), 
3.83 (s, 3H), 4.70 (d, 2H, J = 6.0 Hz), 4.97-5.07 (m, 2H), 5.75-5.85 (m, 1H), 6.59 (br s, 
1H), 6.91 (d, 2H, J = 8.8 Hz) and 7.40 (d, 2H, J = 8.8 Hz); 13C NMR (CDCl3) δ 29.4, 
35.5, 41.1, 52.3, 55.4, 113.8, 115.9, 122.1, 131.4, 136.8, 138.6, 148.3, 160.6, 162.5, 
165.4 and 172.7; mass spectrum (APCI), m/z 361.1110 (M + H)+ (C18H21N2O4S requires 
m/z 361.1144). 
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Cyanomethyl 4-(4-Methoxyphenyl)-2-(pent-4-enamidomethyl)thiazole-5-
carboxylate (3.14). To a stirred solution of 15.0 mg (0.04 mmol) of 3.2 in 0.40 mL of 
3:1 THF_water was added 0.13 mL of 1 N LiOH. The reaction mixture was stirred at 25 
oC for 2 h. The yellow reaction mixture was diluted with MeOH, dried over anhydrous 
Na2SO4 and was concentrated under diminished pressure. The crude product was 
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dissolved in 2 mL of anhydrous DMF and 7.00 mg (0.08 mmol) of NaHCO3 was added, 
followed by 13.0 μL (16.0 mg, 0.21 mmol) of ClCH2CN. The reaction mixture was 
stirred at 25 oC for 3 h under an argon atmosphere. The reaction mixture was 
concentrated under diminished pressure and was purified on a silica gel column (7 × 1 
cm). Elution with ethyl acetate afforded 3.14 as a pale yellow solid: yield 5.8 mg (38%); 
silica gel TLC Rf 0.74 (ethyl acetate); 1H NMR (CDCl3) δ 2.37-2.44 (m, 4H), 3.86 (s, 
3H), 4.73 (d, 2H, J = 6.0 Hz), 4.86 (s, 2H), 5.01-5.10 (m, 2H), 5.79-5.86 (m, 1H), 6.33 
(br s, 1H), 6.95 (d, 2H, J = 8.8 Hz) and 7.42 (d, 2H, J = 8.4 Hz); 13C NMR (CDCl3) δ 
29.5, 31.1, 35.6, 41.2, 48.7, 55.5, 114.1, 114.2, 116.1, 121.5, 131.4, 136.8, 151.2, 160.2, 
161.0, 165.8 and 172.7; mass spectrum (APCI), m/z 386.1177 (M + H)+ (C19H20N3O4S 
requires m/z 386.1175). 
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4-(4-Methoxyphenyl)-2-(pent-4-enamidomethyl)thiazole-5-carboxylate pdCpA 
(3.15). A solution containing 6.0 mg (16 μmol) of cyanomethyl ester 3.14 and 8.0 mg 
(6.0 μmol) of the tris(tetrabutylammonium) salt of pdCpA in 100 μL of 9:1 DMF–Et3N 
was subjected to sonication at room temperature for 4 h. The reaction mixture was 
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diluted with 0.5 mL of 50 mM ammonium acetate, pH 4.5 and centrifuged. The 
supernatant was purified by C18 reversed phase HPLC (250 x 10 mm) using a gradient of 
1% 65% acetonitrile in 50 mM ammonium acetate, pH 4.5, over a period of 45 min. 
The fraction eluting at 19 min was collected and lyophilized to afford 3.15 as a colorless 
solid: yield 3.5 mg (60%); mass spectrum (ESI), m/z 963.1874 (M _ H)- 
(C36H41N10O16P2S requires m/z 963.1898).  
                                            NH O O
O
N
O
FmocHN
 
Methyl 2-(2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)acetamido)-3-(4-
(dimethylamino)phenyl)-3-oxopropanoate (3.17). A solution of 0.50 g (2.00 mmol) of 
3.7 in 5 mL of anhydrous THF was cooled to _78 oC under an argon atmosphere and 
2.00 mL (2.00 mmol) of 1 M sodium bis(trimethylsilyl)amide in THF was added 
dropwise while maintaining the temperature at _78 oC. After 30 min, the resulting yellow 
solution was added via cannula to a stirred solution of 0.43 g (2.00 mmol) of 4-
dimethylaminobenzoyl chloride in 3 mL of anhydrous THF at _78 oC. The reaction 
mixture was stirred at _78 oC for 2 h. The yellow reaction mixture was acidified with 
concentrated HCl until pH ~2 and was then concentrated under diminished pressure. The 
crude product (3.16) was utilized for the next reaction without further purification. To a 
solution of the crude product in 10 mL of anhydrous THF at 0 oC was added 0.79 g (2.00 
mmol) of Fmoc-gly-N-hydroxysuccinimide followed by the dropwise addition of 0.22 
mL (0.20 g, 2.00 mmol) of N-methylmorpholine. The yellow reaction mixture was 
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stirred at 25 oC for 2 h and then concentrated under diminished pressure. The crude 
product was purified on a silica gel column (15 × 2 cm). Elution with 1:1 ethyl 
acetate−hexanes afforded 3.17 as a yellowish solid: yield 0.35 g (34%); silica gel TLC 
Rf 0.27 (1:1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 3.07 (s, 6H), 3.68 (s, 3H), 4.02 
(br s, 2H), 4.21 (s, 1H), 4.39 (d, 2H, J = 6.8 Hz), 5.50 (br s, 1H), 6.08 (d, 1H, J = 7.2 
Hz), 6.64 (d, 2H, J = 8.8 Hz), 7.28 (t, 2H, J = 7.4 Hz), 7.37 (t, 2H, J = 7.4 Hz), 7.48 (d, 
1H, J = 7.2 Hz), 7.59 (d, 2H, J = 7.6 Hz), 7.73 (d, 2H, J = 7.6 Hz) and 8.00 (d, 2H, J = 
8.8 Hz); 13C NMR (CDCl3) δ 44.3, 47.2, 53.4, 55.7, 57.7, 67.4, 114.2, 120.0, 125.2, 
126.8, 127.2, 127.8, 132.2, 141.4, 143.9, 156.6, 164.9, 167.3, 169.0 and 189.1; mass 
spectrum (APCI), m/z 516.2060 (M + H)+ (C29H30N3O6 requires m/z 516.2069).  
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Methyl 2-((((9H-Fluoren-9-yl)methoxy)carbonylamino)methyl)-4-(4-
(dimethylamino)phenyl)oxazole-5-carboxylate (3.18). To a stirred solution of 0.29 g 
(1.12 mmol) of triphenylphosphine and 0.28 g (1.12 mmol) of iodine in 10 mL of 
anhydrous CH2Cl2 was added 0.15 mL (0.11 g, 1.12 mmol) of triethylamine. The dark 
yellow solution was stirred for 5 min and 0.29 g (0.56 mmol) of 3.17 dissolved in 5 mL 
of anhydrous CH2Cl2 was added dropwise. The reaction mixture was stirred for 30 min 
at 25 oC under an argon atmosphere and was then concentrated under diminished 
pressure. The residue was purified on a silica gel column (15 × 2 cm). Elution with 2:3 
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ethyl acetate−hexanes afforded 3.18 as a yellow solid: yield 0.20 g (71%); silica gel 
TLC Rf  0.43 (1: 1 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 3.02 (s, 6H), 3.91 (s, 3H), 
4.23 (t, 1H, J = 5.8 Hz), 4.44 (d, 2H, J = 6.8 Hz), 4.57 (d, 2H, J = 5.6 Hz), 5.67 (br s, 
1H), 6.71 (d, 2H, J = 8.8 Hz), 7.29 (t, 2H, J = 7.4 Hz), 7.38 (t, 2H, J = 7.2 Hz), 7.60 (d, 
2H, J = 7.2 Hz), 7.74 (d, 2H, J = 7.6 Hz) and 7.98 (d, 2H, J = 8.8 Hz); 13C NMR 
(CDCl3) δ 38.2, 40.0, 47.0, 52.0, 67.2, 111.2, 113.7, 119.9, 123.7, 125.0, 127.0, 127.6, 
128.5, 129.6, 141.2, 143.7, 151.5, 156.1, 157.4 and 162.7; mass spectrum (APCI), m/z 
498.1930 (M + H)+ (C29H28N3O5 requires m/z 498.1951). 
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Methyl 4-(4-(Dimethylamino)phenyl)-2-(pent-4-enamidomethyl)oxazole-5-
carboxylate (3.3). To a stirred solution of 0.20 g (0.40 mmol) of 3.18 in 4 mL of 
anhydrous CH2Cl2 was added dropwise 77.0 μL (66.0 mg, 0.78 mmol) of piperidine. The 
reaction mixture was stirred at 25 oC under an argon atmosphere for 2 h and was then 
concentrated under diminished pressure. The residue was dissolved in 5 mL of 
anhydrous THF and 0.15 g (0.78 mmol) of 4-pentenoyloxysuccinimide was added 
followed by 83.0 mg (0.78 mmol) of Na2CO3. The reaction mixture was stirred at room 
temperature for 3 h under an argon atmosphere and was then concentrated under 
diminished pressure. The residue was purified on a silica gel column (7 × 2 cm). Elution 
with 7:3 ethyl acetate−hexanes afforded 3.3 as a pale yellow solid: yield 48.0 mg (33% 
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over two steps); silica gel TLC Rf 0.19 (7:3 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 
2.35-2.42 (m, 4H), 3.02 (s, 6H), 3.90 (s, 3H), 4.61 (d, 2H, J = 5.6 Hz), 4.97-5.08 (m, 
2H), 5.79-5.85 (m, 1H), 6.39 (br s, 1H), 6.71 (d, 2H, J = 8.8 Hz) and 7.96 (d, 2H, J = 8.8 
Hz); 13C NMR (CDCl3) δ 29.3, 35.5, 36.6, 40.0, 52.1, 111.2, 113.7, 115.7, 123.7, 129.6, 
136.7, 151.6, 157.45, 157.50, 162.7 and 172.2; mass spectrum (APCI), m/z 358.1680 (M 
+ H)+ (C19H24N3O4 requires m/z 358.1689). 
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Cyanomethyl 4-(4-(Dimethylamino)phenyl)-2-(pent-4-enamidomethyl)oxazole-5-
carboxylate (3.19). To a stirred solution of 15.0 mg (0.04 mmol) of 3.3 in 0.40 mL 3:1 
THF_water was added 0.08 mL of 1 N LiOH. The reaction mixture was stirred at 25 oC 
for 3 h. The yellow reaction mixture was diluted with MeOH, dried over anhydrous 
Na2SO4 and was concentrated under diminished pressure. The crude product was 
dissolved in 2 mL of anhydrous DMF and 10.0 mg (0.09 mmol) of NaHCO3 was added 
followed by 13.0 μL (16.0 mg, 0.21 mmol) of ClCH2CN. The reaction mixture was 
stirred at 25 oC for 3 h under an argon atmosphere. The reaction mixture was 
concentrated under diminished pressure. The crude product used in the next step without 
further purification.  
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4-(4-(Dimethylamino)phenyl)-2-(pent-4-enamidomethyl)oxazole-5-carboxyl pdCpA 
(3.20). A solution containing 6.0 mg (16 μmol) of cyanomethyl ester 3.19 and 8.0 mg 
(6.0 μmol) of the tris(tetrabutylammonium) salt of pdCpA in 100 μL of 9:1 DMF–Et3N 
was subjected to sonication at room temperature for 2.5 h. The reaction mixture was 
purified by C18 reversed phase HPLC (250 x 10 mm) using a gradient of 1% to 65% 
acetonitrile in 50 mM ammonium acetate, pH 4.5, over a period of 45 min. The fraction 
eluting at 19.5 min was collected and lyophilized to afford 3.20 as a yellow solid: yield-
3.7 mg (66%); mass spectrum (ESI), m/z 960.2440 (M − H)− (C37H44N11O16P2 requires 
m/z 960.2443). 
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Methyl 2-((((9H-Fluoren-9-yl)methoxy)carbonylamino)methyl)-4-(4-
(dimethylamino)phenyl)thiazole-5-carboxylate (3.21). To a stirred solution of 0.16 g 
(0.31 mmol) of 3.17 in 5 mL of anhydrous THF was added 0.25 g (0.62 mmol) of the 
Lawessen’s reagent. The reaction mixture was heated to reflux under an argon 
atmosphere for 1 h. The yellow reaction mixture was diluted with 20 mL of saturated 
NaHCO3 solution. The aqueous layer was extracted with two 25 mL-portions of ethyl 
acetate. The combined organic layer was dried over anhydrous MgSO4 and was 
concentrated under diminished pressure. The crude product was utilized in the next 
reaction without further purification. 
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Methyl 4-(4-(Dimethylamino)phenyl)-2-(pent-4-enamidomethyl)thiazole-5-
carboxylate (3.4). To a stirred solution of the crude 3.21 in 4 mL of anhydrous CH2Cl2 
was added dropwise 64.0 μL (55.0 mg, 0.65 mmol) of piperidine. The reaction mixture 
was stirred at 25 oC under an argon atmosphere for 2 h and was concentrated under 
diminished pressure. The residue was dissolved in 5 mL of anhydrous THF and 0.26 g 
(1.32 mmol) of 4-pentenoyloxysuccinimide was added followed by 83.0 mg (0.78 
mmol) of Na2CO3. The reaction mixture was stirred at room temperature for 3 h under 
an argon atmosphere and concentrated under diminished pressure. The residue was 
purified on a silica gel column (7 × 2 cm). Elution with 7:3 ethyl acetate−hexanes 
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afforded 3.4 as a pale yellow solid: yield 60.0 mg (52% over three steps); silica gel TLC 
Rf 0.17 (7:3 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 2.33-2.42 (m, 4H), 3.00 (s, 6H), 
3.84 (s, 3H), 4.70 (d, 2H, J = 6.0 Hz), 4.99-5.09 (m, 2H), 5.78-5.85 (m, 1H), 6.40 (br s, 
1H), 6.69 (d, 2H, J = 8.8 Hz) and 7.38 (d, 2H, J = 8.8 Hz); 13C NMR (CDCl3) d 29.3, 
35.5, 40.2, 40.9, 52.1, 111.3, 115.8, 116.9, 130.9, 136.7, 137.4, 149.7, 150.9, 162.6, 
163.9 and 172.4; mass spectrum (APCI), m/z 396.1348 (M + H)+ (C19H23N3O3NaS 
requires m/z 396.1358). 
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Cyanomethyl 4-(4-(Dimethylamino)phenyl)-2-(pent-4-enamidomethyl)thiazole-5-
carboxylate (3.22). To a stirred solution of 17.0 mg (0.05 mmol) of 3.4 in 0.4 mL of 3:1 
THF_water was added 0.06 mL of 1 N LiOH. The reaction mixture was stirred at 25 oC 
for 4.5 h. The yellow reaction mixture was diluted with MeOH, dried over anhydrous 
Na2SO4 and was concentrated under diminished pressure. The crude product was 
dissolved in 2 mL of anhydrous DMF and 9.00 mg (0.11 mmol) of NaHCO3 was added 
followed by 25.0 μL (30.0 mg, 0.40 mmol) of ClCH2CN. The reaction mixture was 
stirred at 25 oC for 3 h under an argon atmosphere. The reaction mixture was 
concentrated under diminished pressure and was purified on a silica gel column (7 × 1 
cm). Elution with 3:2 ethyl acetate−hexanes afforded 3.22 as a bright yellow solid: yield 
12.0 mg (65%); silica gel TLC Rf 0.7 (ethyl acetate); 1H NMR (CDCl3) δ 2.36-2.44 (m, 
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4H), 3.02 (s, 6H), 4.71 (d, 2H, J = 2.8 Hz), 4.87 (s, 2H), 5.00-5.10 (m, 2H), 5.79-5.84 
(m, 1H), 6.29 (br s, 1H), 6.71 (d, 2H, J = 8.4 Hz) and 7.39 (d, 2H, J = 8.4 Hz); 13C NMR 
(CDCl3) d 29.3, 35.5, 40.1, 41.0, 48.5, 111.3, 114.2, 115.9, 116.1, 131.0, 135.0, 136.6, 
151.2, 152.8, 160.3, 164.3 and 172.4; mass spectrum (ESI), m/z 421.1316 (M + H)+ 
(C20H22N4O3NaS requires m/z 421.1310). 
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4-(4-(Dimethylamino)phenyl)-2-(pent-4-enamidomethyl)thiazole-5-carboxyl pdCpA 
(3.23). A solution containing 6.0 mg (15 μmol) of cyanomethyl ester 3.22 and 5.7 mg 
(4.2 μmol) of the tris(tetrabutylammonium) salt of pdCpA in 100 μL of 9:1 DMF–Et3N 
was subjected to sonication at room temperature for 4 h. The reaction mixture was 
purified by C18 reversed phase HPLC (250 x 10 mm) using a gradient of 1% to 65% 
acetonitrile in 50 mM ammonium acetate, pH 4.5, over a period of 45 min. The fraction 
eluting at 19.5 min was collected and lyophilized to afford 3.23 as a yellow solid: yield-
2.5 mg (62%); mass spectrum (ESI), m/z 976.2213 (M − H)− (C37H44N11O15P2S requires 
m/z 976.2214). 
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Methyl 2-(2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)acetamido)-3-(4-
cyanophenyl)-3-oxopropanoate (3.25). A solution of 1.00 g (4.00 mmol) of 3.7 in 10 
mL of anhydrous THF was cooled to _78 oC under an argon atmosphere and 4.00 mL 
(4.00 mmol) of 1 M sodium bis(trimethylsilyl)amide in THF was added dropwise while 
maintaining the temperature at _78 oC. After 30 min, the resulting yellow solution was 
added via cannula to a stirred solution of 0.66 g (4.00 mmol) of 4-cyanobenzoyl chloride 
in 3 mL of anhydrous THF at _78 oC. The reaction mixture was stirred at _78 oC for 2 h. 
The yellow reaction mixture was acidified with concentrated HCl until pH ~2 and was 
then concentrated under diminished pressure. The crude product (3.24) was utilized for 
the next reaction without further purification. To a solution of the crude product in 10 
mL of anhydrous THF at 0 oC was added 1.58 g (4.00 mmol) of Fmoc-gly-N-
hydroxysuccinimide followed by a dropwise addition of 0.44 mL (0.40 g, 4.00 mmol) of 
N-methylmorpholine. The yellow reaction mixture was stirred at 25 oC for 2 h and then 
concentrated under diminished pressure. The crude product was purified on a silica gel 
column (15 × 2 cm). Elution with 1:1 ethyl acetate−hexanes afforded 3.25 as a colorless 
oil: yield 0.60 g (38%); silica gel TLC Rf 0.3 (1:1 ethyl acetate−hexanes); 1H NMR 
(CDCl3) δ 3.69 (s, 3H), 4.00 (d, 2H, J = 5.6 Hz), 4.20 (t, 1H, J = 7.0 Hz), 4.39 (d, 2H, J 
= 6.8 Hz), 5.55 (t, 1H, J = 5.4 Hz), 6.15 (d, 1H, J = 7.2 Hz), 7.27 (t, 2H, J = 7.4 Hz), 
7.37 (t, 2H, J = 7.4 Hz), 7.47 (brs, 1H), 7.56 (d, 2H, J = 7.2 Hz), 7.73-7.77 (m, 4H) and 
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8.14 (d, 2H, J = 7.2 Hz); mass spectrum (APCI), m/z 498.1662 (M + H)+ (C28H24N3O6 
requires m/z 498.1665). 
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Methyl 2-((((9H-Fluoren-9-yl)methoxy)carbonylamino)methyl)-4-(4-
cyanophenyl)oxazole-5-carboxylate (3.26). To a stirred solution of 0.21 g (0.80 mmol) 
of triphenylphosphine and 0.2 g (0.8 mmol) of iodine in 10 mL of anhydrous CH2Cl2 
was added 0.11 mL (83.0 mg, 0.80 mmol) of triethylamine. The dark yellow solution 
was stirred for 5 min and 0.20 g (0.40 mmol) of 3.25 dissolved in 5 mL of anhydrous 
CH2Cl2 was added dropwise. The reaction mixture was stirred for 30 min at 25 oC under 
an argon atmosphere and was then concentrated under diminished pressure. The residue 
was purified on a silica gel column (15 × 2 cm). Elution with 1:1 ethyl acetate−hexanes 
afforded 3.26 as a pale yellow solid: yield 0.14 g (73%); silica gel TLC Rf  0.5 (1:1 ethyl 
acetate−hexanes); 
1H NMR (CDCl3) δ 3.95 (s, 3H), 4.22 (t, 1H, J = 6.0 Hz), 4.45 (d, 2H, 
J = 6.8 Hz), 4.61 (d, 2H, J = 5.6 Hz), 5.52 (br s, 1H), 7.28 (t, 2H, J = 7.4 Hz), 7.38 (t, 
2H, J = 7.4 Hz), 7.58 (d, 2H, J = 7.2 Hz), 7.71-7.76 (m, 4H) and 8.20 (d, 2H, J = 8.4 
Hz); 13C NMR (CDCl3) d 29.7, 38.2, 47.0, 52.7, 67.4, 113.7, 118.2, 120.0,124.9, 127.0, 
127.8, 128.7, 130.4, 132.2, 141.3, 143.6, 153.5, 156.1, 160.2 and 161.9; mass spectrum 
(APCI), m/z 479.1479 (M + H)+ (C28H21N3O5 requires m/z 392.1481). 
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Methyl 4-(4-Cyanophenyl)-2-(pent-4-enamidomethyl)oxazole-5-carboxylate (3.5). 
To a stirred solution of 0.14 g (0.29 mmol) of 3.26 in 4 mL of anhydrous CH2Cl2 was 
added dropwise 59.0 μL (51.0 mg, 0.60 mmol) of piperidine. The reaction mixture was 
stirred at 25 oC under an argon atmosphere for 2 h and was then concentrated under 
diminished pressure. The residue was dissolved in 5 mL of anhydrous THF and 0.11 g 
(0.58 mmol) of 4-pentenoyloxysuccinimide was added followed by 37.0 mg (0.44 
mmol) of Na2CO3. The reaction mixture was stirred at room temperature for 3 h under 
an argon atmosphere and was then concentrated under diminished pressure. The residue 
was purified on a silica gel column (7 × 2 cm). Elution with 7:3 ethyl acetate−hexanes 
yielded 3.5 as a pale yellow solid: yield 47.0 mg (37% over two steps); silica gel TLC Rf 
0.29 (7:3 ethyl acetate−hexanes); 1H NMR (CDCl3) δ 2.34-2.40 (m, 4H), 3.92 (s, 3H), 
4.64 (d, 2H, J = 6.0 Hz), 4.96-5.12 (m, 2H), 5.77-5.81 (m, 1H), 6.45 (br s, 1H), 7.72 (d, 
2H, J = 8.8 Hz) and 8.18 (d, 2H, J = 8.8 Hz); mass spectrum (APCI), m/z 340.1210 (M + 
H)+ (C18H18N3O4 requires m/z 340.1219). 
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Cyanomethyl 4-(4-Cyanophenyl)-2-(pent-4-enamidomethyl)oxazole-5-carboxylate 
(3.27). To a stirred solution of 16.0 mg (0.05 mmol) of 3.5 in 0.4 mL of 3:1 THF_water 
was added 0.05 mL of 1 N LiOH. The reaction mixture was stirred at 25 oC for 2 h. The 
yellow reaction mixture was diluted with MeOH, dried over anhydrous Na2SO4 and was 
concentrated under diminished pressure. The crude product was dissolved in 2 mL of 
anhydrous DMF and 12.0 mg (0.14 mmol) of NaHCO3 was added followed by 15.0 μL 
(18.0 mg, 0.24 mmol) of ClCH2CN. The reaction mixture was stirred at 25 oC for 3 h 
under an argon atmosphere. The reaction mixture was concentrated under diminished 
pressure. The crude product was utilized in the next step without further purification. 
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4-(4-Cyanophenyl)-2-(pent-4-enamidomethyl)oxazole-5-carboxyl pdCpA (3.28). A 
solution containing 7.0 mg (20 μmol) of the crude cyanomethyl ester 3.27 and 6.0 mg 
(4.4 μmol) of the tris(tetrabutylammonium) salt of pdCpA in 100 μL of 9:1 DMF–Et3N 
was subjected to sonication at room temperature for 4 h. The reaction mixture was 
purified by C18 reversed phase HPLC (250 x 10 mm) using a gradient of 1% to 65% 
acetonitrile in 50 mM ammonium acetate, pH 4.5, over a period of 45 min. The fraction 
eluting at 17 min was collected and lyophilized to afford 3.28 as a white solid: yield 1.9 
mg (46%). mass spectrum (ESI), m/z 942.1973 (M − H)− (C36H38N11O16P2 requires m/z 
942.1968). 
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Methyl 2-((((9H-Fluoren-9-yl)methoxy)carbonylamino)methyl)-4-(4-
cyanophenyl)thiazole-5-carboxylate (3.29). To a stirred solution of 0.30 g (0.60 mmol) 
of 3.25 in 5 mL of anhydrous THF was added 0.49 g (1.20 mmol) of the Lawessen’s 
reagent. The reaction mixture was heated to reflux under an argon atmosphere for 1 h. 
The yellow reaction mixture was diluted with 20 mL of saturated NaHCO3 solution. The 
aqueous layer was extracted with two 25-mL portions of ethyl acetate. The combined 
organic layer was dried over anhydrous MgSO4 and was then concentrated under 
diminished pressure. The crude product was utilized in the next reaction without further 
purification. 
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Methyl 4-(4-Cyanophenyl)-2-(pent-4-enamidomethyl)thiazole-5-carboxylate (3.6). 
To a stirred solution of the crude 3.29 in 4 mL of anhydrous CH2Cl2 was added dropwise 
0.12 mL (0.10 g, 1.20 mmol) of piperidine. The reaction mixture was stirred at 25 oC 
under an argon atmosphere for 2 h and was then concentrated under diminished 
pressure. The residue was dissolved in 5 mL of anhydrous THF and 0.26 g (1.32 mmol) 
of 4-pentenoyloxysuccinimide was added followed by 83.0 mg (0.78 mmol) of Na2CO3. 
The reaction mixture was stirred at room temperature for 3 h under an argon atmosphere 
and was then concentrated under diminished pressure. The residue was purified on a 
silica gel column (7 × 2 cm). Elution with 1:1 ethyl acetate−hexanes yielded 3.6 as a 
pale yellow solid: yield 47.0 mg (22% over two steps); silica gel TLC Rf 0.29 (7:3 ethyl 
acetate−hexanes); 1H NMR (CDCl3) δ 2.34-2.40 (m, 4H), 3.92 (s, 3H), 4.64 (d, 2H, J = 
6.0 Hz), 4.96-5.12 (m, 2H), 5.77-5.81 (m, 1H), 6.45 (br s, 1H), 7.72 (d, 2H, J = 8.8 Hz) 
and 8.18 (d, 2H, J = 8.8 Hz); 13C NMR (CDCl3) d 29.3, 35.4, 41.1, 52.5, 113.0,116.0, 
118.2, 130.7, 131.9, 134.9, 136.6, 140.1, 145.3, 161.9, 167.2 and 172.6; mass spectrum 
(APCI), m/z 356.0980 (M + H)+ (C18H18N3O3S requires m/z 356.0991). 
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Cyanomethyl 4-(4-Cyanophenyl)-2-(pent-4-enamidomethyl)thiazole-5-carboxylate 
(3.30). To a stirred solution of 16.0 mg (0.05 mmol) of 3.6 in 0.4 mL of 3:1 THF_water 
was added 0.05 mL of 1 N LiOH. The reaction mixture was stirred at 25 oC for 2 h. The 
yellow reaction mixture was diluted with MeOH, dried over anhydrous Na2SO4 and was 
concentrated under diminished pressure. The crude product was dissolved in 2 mL of 
anhydrous DMF and 12.0 mg (0.14 mmol) of NaHCO3 was added followed by 15.0 μL 
(18.0 mg, 0.24 mmol) of ClCH2CN. The reaction mixture was stirred at 25 oC for 3 h 
under an argon atmosphere. The crude product was utilized in the next reaction without 
further purification. 
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4-(4-Cyanophenyl)-2-(pent-4-enamidomethyl)thiazole-5-carboxyl pdCpA (3.31). A 
solution containing 6.0 mg (15.8 μmol) of cyanomethyl ester 3.30 and 6.0 mg (4.4 μmol) 
of the tris(tetrabutylammonium) salt of pdCpA in 100 μL of 9:1 DMF–Et3N was 
subjected to sonication at room temperature for 4 h. The reaction mixture was purified 
by C18 reversed phase HPLC (250 x 10 mm) using a gradient of 1% to 65% acetonitrile 
in 50 mM ammonium acetate, pH 4.5, over a period of 45 min. The fraction eluting at 17 
min was collected and lyophilized to afford 3.31 as a white solid: yield 1.9 mg (45%). 
mass spectrum (ESI), m/z 958.1741 (M _ H)- (C36H38N11O15P2S requires m/z 958.1745). 
Biochemical experiments 
Preparation of Aminoacyl-tRNACUAs. The activation of suppressor tRNACUAs was 
carried out as described previously.117,127 Briefly, a 100-µL reaction mixture (total 
volume) in100 mM Na Hepes, pH 7.5, contained 1.0 mM ATP, 15 mM MgCl2, 100 µg 
of suppressor tRNACUA-COH, 0.5 A260 unit of N-pentenoyl-protected aminoacyl-pdCpA, 
15% DMSO, and 100 units of T4 RNA ligase. The reaction mixture was incubated at 37 
°C for 1.5 h and quenched by the addition of 0.1 vol of 3 M NaOAc, pH 5.2. The N-
protected aminoacylated tRNA was precipitated with 3 vol of cold ethanol. The 
efficiency of ligation was estimated by 8% polyacrylamide–7 M urea gel 
electrophoresis, pH 5.0.128 The N-pentenoyl-protected aminoacyl-tRNACUAs were 
deprotected by treatment with aqueous I2 , typically 2 mM I2 at 25 °C for 30 min. The 
solution was centrifuged, and the supernatant was adjusted to 0.3 M NaOAc and then 
treated with 3 vol of cold ethanol to precipitate the aminoacylated tRNA. The tRNA 
pellet was collected by centrifugation, washed with 70% aq EtOH, air dried and 
dissolved in 10 µL of RNase free water.   
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Preparation of S-30 Extracts from Cells Having Modified Ribosomes. Aliquots (5-
10 μL) from liquid stocks of E. coli BL-21(DE-3) cells, harboring plasmids with a wild-
type or modified rrnB gene, were placed on LB agar supplemented with 100 µg/mL of 
ampicillin and grown at 37 ºC for 16-18 h. One colony was picked from each agar plate 
and transferred into 3 mL of LB medium supplemented with 100 µg/mL of ampicillin 
and 0.5 mM IPTG.  
   The cultures were grown at 37 ºC for 3-6 h in a thermostated shaker until OD600 ~ 
0.15-0.3 was reached, diluted with LB medium supplemented with 100 µg/mL 
ampicillin, 1 mM IPTG and 3 µg/mL of erythromycin (for selectively enhancing the 
modified ribosome fraction) until OD600 0.01 was reached, and then grown at 37 ºC for 
12-18 h. The optimal concentration of the final cultures was OD600 0.5-1.0.  Cells were 
harvested by centrifugation (5000 × g, 4 ºC, 10 min), washed three times with S-30 
buffer (1 mM Tris-OAc, pH 8.2, containing 1.4 mM Mg(OAc)2, 6 mM KOAc and 
0.1mM DTT) supplemented with β-mercaptoethanol (0.5 mL/L) and once with S-30 
buffer having 0.05 mL/L β-mercaptoethanol.  
    The weight of the wet pellet was estimated and 1.27 mL of S-30 buffer was added to 
suspend each 1 g of cells. The volume of the suspension was measured and used for 
estimating the amount of other components. Pre-incubation mixture (0.3 mL) (0.29 M 
Tris, pH 8.2, containing 9 mM Mg(OAc)2, 13 mM ATP, 84 mM phosphoenol pyruvate, 
4.4 mM DTT and 5 µM amino acids mixture), 15 units of pyruvate kinase and 10 μg of 
lyzozyme were added per 1 mL of cell suspension and the resulting mixture was 
incubated at 37 ºC for 30 min. The incubation mixture was then frozen at – 80 ºC (~30 
min), melted (37 ºC, 30 min), and again frozen and melted at room temperature (~30 
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min). Ethylene glycol tetraacetic acid (EGTA) was then added to 2.5 mM final 
concentration and the cells were incubated at 37 ºC for 30 min. The same molar 
concentration of CaCl2 was added, mixed well and frozen (– 80 ºC, 30 min). The frozen 
mixture was centrifuged (15,000 × g, 4 ºC, 1 h) and the supernatant was stored in 
aliquots at – 80 ºC. 
In vitro Protein Translation. Protein translation reactions were carried out in 15-1700 
µL of incubation mixture containing 0.3 µL/µL of S-30 system, 170 ng/µL of plasmid, 
35 mM Tris acetate, pH 7.4, 190 mM potassium glutamate, 30 mM ammonium acetate, 
2 mM DTT, 0.2 mg/mL total E. coli tRNA, 3.5% PEG 6000, 20 µg/mL folinic acid, 20 
mM ATP and GTP, 5 mM CTP and UTP, 100 µM amino acids mixture, 0.5 µCi/µL of 
35S-methionine and 1 μg/mL rifampicin. In the case of plasmids having a gene with a 
TAG codon, an activated suppressor tRNA was added to a concentration of 1.5 µg/µL. 
Reactions were carried out at 37 °C for 1 h (for 15-µL reaction mixtures) to 1.5 h (for 
1700-uL reaction mixtures) and terminated by chilling on ice. Aliquots from in vitro 
translation mixtures were analyzed by SDS-PAGE followed by quantification of the 
radioactive bands by phosphorimager analysis (for 15-µL reaction mixtures).  
Purification of GFP. Samples of GFP were diluted with 50 mM Tris-HCl, pH 8.2, and 
applied to a 100 µL Ni-NTA agarose column that had been equilibrated with the same 
buffer. The column was washed with 1 mL of the same buffer and GFP was eluted with 
500 µL of the same buffer containing 250 mM imidazole. A 50-µL column of DEAE-
Sepharose was equilibrated with two 500-µL portions of 25 mM Tris-HCl, pH 7.4. 
Samples of GFP purified by Ni-NTA chromatography were diluted 3-fold in the same 
buffer and applied to the resin. The column was washed with four 500-µL portions of 
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the same buffer. GFP was eluted from the resin with 0.5 mM NaCl in 25 mM Tris-HCl, 
pH 7.4. The fractions were analyzed on a 15% polyacrylamide gel, stained using 
Coomassie R-250, and then destained in water. The appropriate fractions were combined 
and fluorescence was measured.    
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CHAPTER 4 
 
4. β-AMINO ACID ANALOGUES AS PROBES FOR THE STUDY OF THE REGIO- 
AND STEREOSELECTIVITY OF MODIFIED RIBOSOMES 
4.1. Introduction 
    The biological and physical properties of peptides and proteins are critically dependent 
on their folded conformations.129 For decades scientists have been captivated by the 
question of how the amino acid sequence directs the folding of a polypeptide into its 
bioactive conformation, and how these structures are stabilized.129 It has slowly emerged 
that like proteins, there are several other types of biopolymers, such as β-peptides,130 γ-
peptides,131 peptoids132 etc., which can assume well-defined three-dimensional structures. 
These non-natural biopolymers have drawn much attention because they can provide 
systems to study protein folding and stabilization. 
    β-Peptides are non-natural biopolymers having β-amino acids as building blocks. 
Although β-amino acids are found in cells, they are not found in ribosomally synthesized 
proteins or enzymes.133 β-peptides are promising antimicrobial candidates, they can adopt 
secondary structures. Additionally, the β-peptide backbone is resistant to proteolysis 
unlike their natural counterparts.134 Nonetheless, the availability of β-peptides is limited 
due to the constraints of synthetic and semi-synthetic methods. The largest β-mimetic 
reported is only 17 amino acid long.135 Therefore, in vitro protein synthesis using 
modified ribosomes can be an efficient tool for the synthesis of proteins or long peptides 
with β-amino acids. 
     The ribosomal PTC is biased against β-amino acids.59 From the experiments of  
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Roberts and coworkers, it is evident that β-amino acids can be accommodated in the A-
site of the PTC but for some reason, they do not take part in peptide bond formation.56 
The modified ribosomes used for the incorporation of D-amino acids were also unable to 
incorporate β-amino acids to a significant extent. This implies that the architecture of 
ribosomal PTC may have a stronger bias for β-amino acids than D-amino acids.59 
Therefore, a new library of modified ribosomes was prepared, having modifications in 
two regions of the PTC. A dual selection process was used to identify the modified 
ribosomes, which would be able to incorporate α-amino acids as well as β-amino acids. It 
is well known that erythromycin prevents bacterial translation by binding to a site close 
to the PTC.136,137 Therefore, altered erythromycin resistance would indicate the alteration 
in the architecture at a site close to the PTC. In addition, erythromycin resistance also 
permitted the identification of mutations that caused extensive alterations of PTC 
architecture, characterization of the modified ribosomes in the presence of wild-type 
ribosomes and maximization of the levels of modified ribosomes. In order to have a 
moderate erythromycin resistance a library of E. coli having plasmids with modifications 
in 23S rRNA gene in nucleotides 2057-2063 was prepared.59 Eight different 23S rRNA 
variants having 4_8 times higher erythromycin resistance than wild-type variants were 
selected, tested for an enhanced sensitivity to β3-puromycin (Figure 4.1) and were 
subjected to a second round of modification. In this round of mutagenesis the eight 
variants were used as templates and were modified in regions 2502-2507 or 2496-2501. 
Thus a new library of modified ribosomes was prepared having modifications in two 
regions of 23S rRNA (2057-2063 and 2502-2507 or 2496-2501).53,59 The modified 
ribosomes were again subjected to erythromycin and β3-puromycin selection. Five clones 
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giving desired β3-puromycin sensitivity were used for the preparation of S-30 systems 
and were shown to incorporate five different β-alanine analogues into full length DHFR 
by nonsense codon suppression.53 
N
NN
N
N
O
OHNH
HO
O
β3-puromycin
H2N
MeO
N
NN
N
N
O
OHNH
HO
H2N O
β2-puromycin  
Figure 4.1. Chemical structures of the puromycin derivatives used for selection.  
    In the study mentioned above, the modified ribosomes were selected using a single 
puromycin analogue (β3-puromycin) where the side chain was at the 3-position with an S-
configuration. Since PTC is sensitive to the spatial orientation of the side chains of amino 
acids, it was anticipated that the modified ribosomes might prefer the aminoacyl-tRNAs 
with regio- and stereoselectivity similar to the configuration of the β-amino acid moiety 
in the β3-puromycin used for ribosome selection.138 Thus, several aminoacyl-tRNACUAs 
containing four different methyl-β-alanine isomers (Figure 4.2) and four constrained 
cyclic-β-amino acid isomers (Figure 4.3) as probes were prepared in order to study the 
regio- and stereochemical predisposition of the modified ribosomes.138 
         
H2N OH
O
H2N OH
O
H2N OH
O
H2N OH
O
4.1 4.2 4.3 4.4  
Figure 4.2. Methyl β-alanine analogues used as probes.  
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   Additionally, β2-puromycin, having opposite regiochemistry compared to β3-
puromycin, was further employed in order to test the idea, that modified ribosomes 
facilitate the incorporation of amino acids having similar regio- and stereochemistry as 
the puromycin derivative used for selection.138  
                 
COOH
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COOH
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NH2
COOH
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1
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  4.5
1R 2S
  4.6
1S 2R
  4.7
1R2R
  4.8
1S 2S  
Figure 4.3. Cyclic β-amino acids used as probes.  
4.2. Results 
  
    Misacylated suppressor tRNACUAs carrying individual β-amino acids were prepared 
from β-aminoacyl-pdCpAs. Schemes 4.1-4.6 describe the preparation of the suppressor 
tRNACUAs. Commercially available 4.1 and 4.2 were first protected with a pentenoyl 
group using pentenoyloxysuccinimide. The crude products were then activated as the 
corresponding cyanomethyl esters using chloroacetonitrile and triethylamine in 50% and 
65% yields for 4.1 and 4.2, respectively. The cyanomethyl esters (4.9 and 4.11) were then 
coupled with tetrabutylammonium salt of pdCpA to afford the corresponding pdCpA 
derivatives 4.10 and 4.12 in quantitative yields. 
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Scheme 4.1.  Synthesis of misacylated suppressor tRNACUA carrying β-amino acid 4.1.  
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Scheme 4.2. Synthesis of misacylated suppressor tRNACUA carrying β-amino acid 4.2.  
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    The pdCpA derivatives of the cyclic β-amino acids 4.5-4.8 were synthesized similarly. 
Commercially available 4.5, 4.6, 4.7 and 4.8 were first treated with 
pentenoyloxysuccinimide to protect the free amine groups. The crude acids were then 
activated as corresponding cyanomethyl esters 4.13, 4.15, 4.17 and 4.19, respectively. 
Compounds 4.13, 4.15, 4.17 and 4.19 were afforded in 25%, 34%, 27% and 34% yields, 
respectively. The cyanomethyl esters were coupled with tetrabutylammonium salt of 
pdCpA to afford individual pdCpA derivatives in quantitative yields. 
Scheme 4.3. Synthesis of misacylated suppressor tRNACUA carrying β-amino acid 4.5.   
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Scheme 4.4. Synthesis of misacylated suppressor tRNACUA carrying β-amino acid 4.6. 
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Scheme 4.5. Synthesis of misacylated suppressor tRNACUA carrying β-amino acid 4.7.   
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Scheme 4.6. Synthesis of suppressor tRNACUA carrying β-amino acid 4.8.  
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   The pdCpA derivatives were ligated to abbreviated suppressor tRNACUA using T4 RNA 
ligase. The ligated tRNAs were deprotected using 5 mM iodine and were used in cell-free 
protein synthesizing systems. The results are shown in Table 4.1-4.3.138  
Table 4.1. Incorporation of β-amino acids 4.1-4.4 into position 10 of E. coli DHFR by 
the use of different S-30 systems having different modified ribosomes selected using β3-
puromycin. The experiments were conducted by Dr. Rumit Maini.138 
 
Clone    Suppression efficiency in different   S-30 
systems 
 Region 1 Region 2 _ 4.1 4.2 4.3 4.4 
0403x4 2057AGCGUGA206
3 
2502AGCCAG2507 0.07±
0.05 
2.7±1.1 3±1.3 6.7± 
1.1 
11.8± 
1.5 
040321 2057AGCGUGA206
3 
2502AGAUAA2507 0.12±
0.04 
2.1±1.0 3.4± 
1.9 
1.8± 
0.8 
8.3±1.5 
040329 2057AGCGUGA206
3 
2502UGGCAG2507 0.06±
0.03 
1.8±0.4 2.8± 
0.6 
5.3± 
1.5 
9.8±1.1 
040217 
Wild-
type 
2057AGCGUGA206
3 
2057GAAAGAC206
3 
 
2496AUAGAA2501 
2496CACCUC2501 
2502GAUGUC2507 
0.2± 
0.1 
3.6±0.5 10.6± 
3.3 
10.6±
3.3 
17.8± 
1.2 
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Table 4.2. Incorporation of β-amino acids 4.5-4.8 into position 10 of E.coli DHFR by the 
use of S-30 systems having different modified ribosomes selected using β3-puromycin. 
The experiments were conducted by Dr. Rumit Maini.138 
 
Clone                      Suppression efficiency in different S-30 systems 
 _ 4.5 4.6 4.7 4.8 
0403x4 0.07±0.05 0.5±0.20 2.0±0.15 0.7±0.25 1.7±0.20 
040321 0.12±0.04 1.0±0.30 2.8±0.26 0.9±0.20 2.0±0.60 
040329 0.06±0.03 1.8±0.35 2.9±0.30 2.2±0.25 3.1±0.50 
040217 0.2±0.1 0.8±0.15 3.9±0.30 1.5±0.10 1.9±0.20 
 
Table 4.3. Incorporation of β-amino acids 4.1-4.4 into position 10 of E.coli DHFR by the 
use of S-30 systems having different modified ribosomes selected using β2-puromycin. 
The experiments were conducted by Dr. Rumit Maini.138  
 
Clone                      Suppression efficiency in different S-30 systems 
 _ 4.1 4.2 4.3 4.4 
010374 0.05±0.02 5.5±0.20 7.1±1.0 4.6±0.5 5.2±1.1 
010355 0.4±0.1 0.4±0.1 3.8±0.3 2.3±0.2 1.2±0.3 
 
4.4. Discussion 
    The β-amino acids were incorporated into DHFR by the suppression of UAG stop 
codon at position 10 of DHFR mRNA using chemically misacylated tRNA with CUA 
anticodon and S-30 systems having modified ribosomes. In order to chemically 
misacylate tRNACUA, the pdCpA derivatives of individual β-amino acids were prepared 
first. The free amino group of the β-amino acids (4.1, 4.2 and 4.5-4.8) was first protected 
by pentenoyl group using pentenoyloxysuccinimide. The crude acids were subsequently 
activated as cyanomethyl esters using chloroacetonitrile in varying yields (Schemes 4.1-
4.6). The cyanomethyl esters were then coupled with tetrabutylammonium salt of pdCpA 
to afford the pdCpA derivatives. The pdCpA derivatives were obtained quantitatively in 
all of the cases. Subsequently the pdCpA derivatives were ligated to abbreviated 
suppressor tRNACUAs using T4 RNA ligase, deprotected and used in in vitro protein 
synthesis as probes. S-30 systems were prepared from E. coli colonies harboring different 
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modified ribosomes. The modified ribosomes were selected either with β3-puromycin or 
β2-puromycin (Figure 4.1) and tested for their ability to incorporate different β-amino 
acids into position 10 of DHFR.              
    S-30 systems having modified ribosomal clones 040329, 040321, 0403x4, and 040217 
were selected using β3-puromycin. When employed to incorporate β-amino acids 4.1-4.4 
into DHFR, the modified ribosomes displayed good regioselectivity, predominantly 
accepting 3-substituted methyl-β-alanines 4.3 and 4.4 (up to 5-fold) than 2-substituted β-
amino acids 4.1 and 4.2 (Table 4.1). β3-puromycin has a 4-methoxybenzyl group at 
position 3 (Figure 4.1), in agreement with the observed predisposition displayed by the 
modified ribosomes for 3-substituted methyl-β-alanine isomers. In addition, all four 
modified ribosomes preferred stereoisomer 3(S)-methyl-β-alanine (4.4) compared to 
3(R)-methyl-β-alanine (4.3); 4.4 accurately reflects the stereochemistry of the β-tyrosine 
moiety in β3-puromycin. The ribosomal clones were also unable to discriminate between 
2-substituted methyl-β-alanines 4.1 and 4.2 presumably because of the lack of a 
substituent at position 2 of the β-amino acid in β3-puromycin.138 
    The amino acid moiety in β2-puromycin has a benzyl group at position 2 with R-
stereochemistry (Figure 4.1). It was assumed that these clones would favor 2-methyl-β-
alanine derivatives 4.1 and 4.2, possibly with enhanced selectivity for R-isomer 4.1. In 
accordance with the regioisomerism of the amino acid moiety in β2-puromycin used in 
the selection experiments, both ribosomal clones incorporated 2-methyl-β-alanine 
isomers 4.1 and 4.2 with moderately increased yields over the 3-methyl-β-alanine 
derivatives; this is illustrated in Table 4.3 for the incorporation of the four β-amino acids 
into position 10 of DHFR by clone 010335 and clone 010374.138 
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    It was anticipated that the modified ribosomes would show greater regio- and 
stereoselectivity with rigid 2, 3-disubstituted β-amino acids (Figure 4.3). The results were 
completely opposite to the expectations. There was no regio- or stereoselectivity 
displayed by the modified ribosomes for cyclic β-amino acids (Table 4.2). This is 
presumably because of the fact that the cyclic β-amino acids were poorly recognized by 
the modified ribosomes as depicted by their poor suppression yields (Table 4.2).138  
    Thus, the ribosomal incorporation of eight new β-amino acids into full length DHFR 
was successfully demonstrated. The β-amino acids had different regio- and 
stereochemical properties and were used as probes to verify that the modified ribosomes, 
generally, displayed preferred regio- and stereoselectivity in accordance with the regio- 
and stereochemistry of the β-puromycin derivatives used for their selection.  
4.4 Experimental 
                                          
OCH2CN
H
N
OO
 
N-(4-Pentenoyl)-2R-methyl-β-alanine Cyanomethyl ester (4.9). To a solution 
containing 100 mg (0.97 mmol) of 4.1 and 245 mg (2.91 mmol) of NaHCO3 in 5 mL of 
1:1 dioxane–H2O was added 216 mg (1.10 mmol) of 4-pentenoyloxysuccinimide. The 
reaction mixture was stirred at room temperature for 24 h under an argon atmosphere. 
The reaction was quenched by the addition of 15 mL of 1 N aq NaHSO4 and the aqueous 
layer was extracted with two 25-mL portions of ethyl acetate. The combined organic 
extract was dried over anhydrous MgSO4 and concentrated under diminished pressure. 
The crude product was then dissolved in 5 mL of acetonitrile. To this solution were added 
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600 μL (435 mg, 4.40 mmol) of triethylamine and 260 μL (309 mg, 4.09 mmol) of 
chloroacetonitrile. The reaction mixture was stirred at room temperature for 24 h at which 
time 20 mL of ethyl acetate was added. The organic layer was washed with 10 mL of 1 N 
aq NaHSO4 followed by 10 mL of brine, dried over anhydrous MgSO4 and concentrated 
to dryness under diminished pressure, affording a crude residue. The crude product was 
purified by flash silica gel column chromatography using 1:1 ethyl acetate–hexanes for 
elution to obtain 4.9 as colorless oil: yield 108 mg (50%); Rf 0.5 (1:1 ethyl acetate–
hexanes); 1H NMR (CDCl3) δ 1.16 (d, 3H, J = 7.2 Hz), 2.20-2.24 (m, 2H), 2.29-2.34 (m, 
2H), 2.75-2.80 (m, 1H), 3.26-3.33 (m, 1H), 3.43-3.49 (m, 1H), 4.70 (s, 2H), 4.94-5.03 
(m, 2H), 5.72-5.79 (m, 1H) and 6.16 (br s, 1H); 13C NMR (CDCl3) δ 14.5, 29.5, 35.6, 
39.3, 41.6, 48.6, 114.5, 115.6, 136.9, 172.8 and 173.9; mass spectrum (APCI), m/z 
225.1242 (M + H)+ (C11H17N2O3 requires m/z 225.1239). 
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N-(4-Pentenoyl)-2R-methyl-β-alanyl-pdCpA (4.10). To a 1.5-mL eppendorf tube 
containing 5.30 mg (3.70 μmol) of the tris(tetrabutylammonium) salt of pdCpA was 
added 10.0 mg (44.6 μmol) of 4.9 dissolved in 100 μL of 9:1 DMF–Et3N. After 2 h of 
sonication, the reaction mixture was purified by C18 reversed phase HPLC (250 x 10 mm) 
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using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate, pH 4.5, over a 
period of 45 min. The fraction eluting at 13.9 min was collected, combined and 
lyophilized to afford 4.10 as a colorless solid: yield 3.0 mg (100%); mass spectrum (ESI), 
m/z 802.1937 (M – H)- (C28H38N9O15P2 requires m/z 802.1963). 
                                              
OCH2CN
H
N
OO
 
N-(4-Pentenoyl)-2S-methyl-β-alanine Cyanomethyl ester (4.11). To a solution 
containing 100 mg (0.97 mmol) of 4.2 and 245 mg (2.91 mmol) of NaHCO3 in 5 mL of 
1:1 dioxane–H2O was added 216 mg (1.10 mmol) of 4-pentenoyloxysuccinimide. The 
reaction mixture was stirred at room temperature for 24 h under argon. The reaction was 
quenched by the addition of 15 mL of 1 N aq NaHSO4 and the aqueous layer was 
extracted with two 25-mL portions of ethyl acetate. The combined organic extract was 
dried over anhydrous MgSO4 and concentrated under diminished pressure. The crude 
product was then dissolved in 5 mL of acetonitrile. To this solution were added 600 μL 
(435 mg, 4.40 mmol) of triethylamine and 260 μL (309 mg, 4.09 mmol) of 
chloroacetonitrile. The reaction mixture was stirred at room temperature for 24 h at which 
time 20 mL of ethyl acetate was added. The organic layer was washed with 10 mL of 1 N 
aq NaHSO4 followed by 10 mL of brine, dried over anhydrous MgSO4 and concentrated 
to dryness under diminished pressure, affording a crude residue. The crude product was 
purified by flash silica gel column chromatography using 1:1 ethyl acetate–hexanes for 
elution to obtain 4.11 as colorless oil: yield 140 mg (65%); Rf 0.5 (1:1 ethyl acetate–
hexanes); 1H NMR (CDCl3) δ 1.15 (d, 3H, J = 7.2 Hz), 2.19-2.31 (m, 4H), 2.74-2.77 (m, 
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1H), 3.29-3.32 (m, 1H), 3.41-3.44 (m, 1H), 4.69 (s, 2H), 4.93-5.02 (m, 2H), 5.71-5.78 
(m, 1H) and 6.23 (br s, 1H); 13C NMR (CDCl3) δ 14.5, 29.5, 35.6, 39.3, 41.6, 48.6, 114.5, 
115.6, 136.9, 172.8 and 173.9; mass spectrum (APCI), m/z 225.1239 (M + H)+ 
(C11H17N2O3 requires m/z 225.1239). 
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N-(4-Pentenoyl)-2S-methyl-β-alanyl-pdCpA (4.12). To a 1.5-mL eppendorf tube 
containing 5.30 mg (3.70 μmol) of the tris(tetrabutylammonium) salt of pdCpA was 
added 10.0 mg (44.6 μmol) of 4.11 dissolved in 100 μL of 9:1 DMF–Et3N. After 2 h of 
sonication, the reaction mixture was purified by C18 reversed phase HPLC (250 x 10 mm) 
using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate, pH 4.5, over a 
period of 45 min. The fraction eluting at 13.9 min was collected, combined and 
lyophilized to afford 4.12 as a colorless solid: yield 3.0 mg (100%); mass spectrum (ESI), 
m/z 802.1945 (M – H)- (C28H38N9O15P2 requires m/z 802.1963). 
                                                
COOCH2CN
NH
O
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(1R, 2S)-Cyanomethyl 2-(Pent-4-enamido)cyclopentanecarboxylate (4.13). To a 
solution containing 17.0 mg (0.13 mmol) of 4.5 and 34.0 mg (0.40 mmol) of NaHCO3 in 
2 mL of 1:1 dioxane–H2O was added 39.0 mg (0.20 mmol) of 4-
pentenoyloxysuccinimide. The reaction mixture was stirred at room temperature for 24 h 
under argon. The reaction was quenched by the addition of 8 mL of 1 N aq NaHSO4 and 
the aqueous layer was extracted with two 15-mL portions of ethyl acetate. The combined 
organic extract was dried over anhydrous MgSO4 and concentrated under diminished 
pressure. The crude product was then dissolved in 2 mL of acetonitrile. To this solution 
were added 66.0 μL (49.0 mg, 0.48 mmol) of triethylamine and 61.0 μL (71.0 mg, 0.95 
mmol) of chloroacetonitrile. The reaction mixture was stirred at room temperature for 24 
h at which time 20 mL of ethyl acetate was added. The organic layer was washed with 10 
mL of 1 N aq NaHSO4 followed by 10 mL of brine, dried over anhydrous MgSO4 and 
concentrated to dryness under diminished pressure, affording a crude residue. The crude 
product was purified by flash silica gel column chromatography using 1:1 ethyl acetate–
hexanes for elution to obtain 4.13 as colorless oil: yield 8.1 mg (25% over two steps); Rf 
0.45 (1:1 ethyl acetate–hexanes); 1H NMR (CDCl3) δ 1.62-1.70 (m, 2H), 1.82-1.86 (m, 
1H), 1.95-2.05 (m, 3H), 2.22-2.26 (m, 2H), 2.32-2.37 (m, 2H), 3.10 (q, 1H, J = 7.4 Hz), 
4.54 (quint, 1H, J = 7.6 Hz), 4.66 (s, 2H), 4.97-5.07 (m, 2H) and 5.76-5.84 (m, 2H); 13C 
NMR (CDCl3) δ 22.3, 27.9, 29.5, 31.9, 35.7, 46.5, 48.4, 52.7, 114.5, 115.7, 137.1, 172.3 
and 173.1; mass spectrum (EI), m/z 250.1315 (M + H)+ (C13H18N2O3 requires m/z 
250.1318). 
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(1R, 2S)-2-(pent-4-enamido)cyclopentanecarboxyl pdCpA (4.14). To a 1.5-mL 
eppendorf tube containing 5.00 mg (3.66 μmol) of the tris(tetrabutylammonium) salt of 
pdCpA was added 4.50 mg (18.0 μmol) of 4.13 dissolved in 100 μL of 9:1 DMF–Et3N. 
After 3 h of sonication, the reaction mixture was purified by C18 reversed phase HPLC 
(250 x 10 mm) using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate, 
pH 4.5, over a period of 45 min. The fraction eluting at 13.5 min was collected, combined 
and lyophilized to afford 4.14 as a colorless solid: yield 3.0 mg (100%); mass spectrum 
(ESI), m/z 828.2126 (M – H)- (C30H40N9O15P2 requires m/z 828.2119). 
                                              
COOCH2CN
NH
O
 
(1S, 2R)-Cyanomethyl 2-(Pent-4-enamido)cyclopentanecarboxylate (4.15). To a 
solution containing 20.8 mg (0.16 mmol) of 4.6 and 40.0 mg (0.48 mmol) of NaHCO3 in 
2 mL of 1:1 dioxane–H2O was added 49.0 mg (0.25 mmol) of 4-
pentenoyloxysuccinimide. The reaction mixture was stirred at room temperature for 24 h 
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under argon. The reaction was quenched by the addition of 8 mL of 1 N aq NaHSO4 and 
the aqueous layer was extracted with two 15-mL portions of ethyl acetate. The combined 
organic extract was dried over anhydrous MgSO4 and concentrated under diminished 
pressure. The crude product was then dissolved in 2 mL of acetonitrile. To this solution 
were added 66.0 μL (49.0 mg, 0.48 mmol) of triethylamine and 61.0 μL (71.0 mg, 0.95 
mmol) of chloroacetonitrile. The reaction mixture was stirred at room temperature for 24 
h at which time 20 mL of ethyl acetate was added. The organic layer was washed with 10 
mL of 1 N aq NaHSO4 followed by 10 mL of brine, dried over anhydrous MgSO4 and 
concentrated to dryness under diminished pressure, affording a crude residue. The crude 
product was purified by flash silica gel column chromatography using 1:1 ethyl acetate–
hexanes for elution to obtain 4.15 as colorless oil: yield 11 mg (34% over two steps); Rf 
0.45 (1:1 ethyl acetate–hexanes); 1H NMR (CDCl3) δ 1.60-1.66 (m, 2H), 1.82-1.84 (m, 
1H), 1.93-2.00 (m, 3H), 2.20-2.24 (m, 2H), 2.30-2.33 (m, 2H), 3.08 (q, 1H, J = 7.4 Hz), 
4.52 (quint, 1H, J = 7.6 Hz), 4.64 (s, 2H), 4.95-5.05 (m, 2H) and 5.74-5.82 (m, 2H); 13C 
NMR (CDCl3) δ 22.3, 27.8, 29.5, 31.9, 35.7, 46.5, 48.4, 52.6, 114.5, 115.6, 137.1, 172.2 
and 173.1; mass spectrum (EI), m/z 250.1316 (M + H)+ (C13H18N2O3 requires m/z 
250.1318). 
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(1S, 2R)-2-(Pent-4-enamido)cyclopentanecarboxyl pdCpA (4.16). To a 1.5-mL 
eppendorf tube containing 5.00 mg (3.66 μmol) of the tris(tetrabutylammonium) salt of 
pdCpA was added 4.50 mg (18.0 μmol) of 4.15 dissolved in 100 μL of 9:1 DMF–Et3N. 
After 3 h of sonication, the reaction mixture was purified by C18 reversed phase HPLC 
(250 x 10 mm) using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate, 
pH 4.5, over a period of 45 min. The fraction eluting at 13.5 min was collected, combined 
and lyophilized to afford 4.16 as a colorless solid: yield 3.0 mg (100%); mass spectrum 
(ESI), m/z 828.2124 (M – H)- (C30H40N9O15P2 requires m/z 828.2119). 
COOCH2CN
NH
O
 
(1R, 2R)-Cyanomethyl 2-(Pent-4-enamido)cyclopentanecarboxylate (4.17). To a 
solution containing 19.0 mg (0.15 mmol) of 4.7 and 40.0 mg (0.48 mmol) of NaHCO3 in 
2 mL of 1:1 dioxane–H2O was added 49.0 mg (0.25 mmol) of 4-
pentenoyloxysuccinimide. The reaction mixture was stirred at room temperature for 24 h 
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under argon. The reaction was quenched by the addition of 8 mL of 1 N aq NaHSO4 and 
the aqueous layer was extracted with two 15-mL portions of ethyl acetate. The combined 
organic extract was dried over anhydrous MgSO4 and concentrated under diminished 
pressure. The crude product was then dissolved in 2 mL of acetonitrile. To this solution 
were added 66.0 μL (49.0 mg, 0.48 mmol) of triethylamine and 61.0 μL (71.0 mg, 0.95 
mmol) of chloroacetonitrile. The reaction mixture was stirred at room temperature for 24 
h at which time 20 mL of ethyl acetate was added. The organic layer was washed with 10 
mL of 1 N aq NaHSO4 followed by 10 mL of brine, dried over anhydrous MgSO4 and 
concentrated to dryness under diminished pressure, affording a crude residue. The crude 
product was purified by flash silica gel column chromatography using 1:1 ethyl acetate–
hexanes for elution to obtain 4.17 as colorless oil: yield 10 mg (27% over two steps); Rf 
0.45 (1:1 ethyl acetate–hexanes); 1H NMR (CDCl3) δ 1.48-1.54 (m, 1H), 1.74-1.81 (m, 
2H), 1.90-1.95 (m, 1H), 2.02-2.06 (m, 1H), 2.11-2.16 (m, 1H), 2.22-2.25 (m, 2H), 2.33-
2.39 (m, 2H), 2.63 (q, 1H, J = 8.4 Hz), 4.33 (quint, 1H, J = 8.0 Hz), 4.64-4.76 (m, 2H), 
4.99-5.08 (m, 2H), 5.66 (br s, 1H) and 5.77-5.83 (m, 1H); 13C NMR (CDCl3) δ 23.1, 28.7, 
29.6, 32.7, 35.7, 48.6, 50.4, 55.3, 114.7, 115.8, 137.0, 172.5 and 173.4; mass spectrum 
(EI), m/z 250.1318 (M + H)+ (C13H18N2O3 requires m/z 250.1318). 
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(1R, 2R)-2-(pent-4-enamido)cyclopentanecarboxyl pdCpA (4.18). To a 1.5-mL 
eppendorf tube containing 5.00 mg (3.66 μmol) of the tris(tetrabutylammonium) salt of 
pdCpA was added 4.50 mg (18.0 μmol) of 4.17 dissolved in 100 μL of 9:1 DMF–Et3N. 
After 3 h of sonication, the reaction mixture was purified by C18 reversed phase HPLC 
(250 x 10 mm) using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate, 
pH 4.5, over a period of 45 min. The fraction eluting at 13.5 min was collected, combined 
and lyophilized to afford 4.18 as a colorless solid: yield 3.0 mg (100%); mass spectrum 
(ESI), m/z 828.2123 (M – H)- (C30H40N9O15P2 requires m/z 828.2119). 
                                            
COOCH2CN
NH
O
 
(1S, 2S)-Cyanomethyl 2-(Pent-4-enamido)cyclopentanecarboxylate (4.19). To a 
solution containing 18.0 mg (0.14 mmol) of 4.8 and 40.0 mg (0.48 mmol) of NaHCO3 in 
2 mL of 1:1 dioxane–H2O was added 49.0 mg (0.25 mmol) of 4-
pentenoyloxysuccinimide. The reaction mixture was stirred at room temperature for 24 h 
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under argon. The reaction was quenched by the addition of 8 mL of 1 N aq NaHSO4 and 
the aqueous layer was extracted with two 15-mL portions of ethyl acetate. The combined 
organic extract was dried over anhydrous MgSO4 and concentrated under diminished 
pressure. The crude product was then dissolved in 2 mL of acetonitrile. To this solution 
were added 66.0 μL (49.0 mg, 0.48 mmol) of triethylamine and 61.0 μL (71.0 mg, 0.95 
mmol) of chloroacetonitrile. The reaction mixture was stirred at room temperature for 24 
h at which time 20 mL of ethyl acetate was added. The organic layer was washed with 10 
mL of 1 N aq NaHSO4 followed by 10 mL of brine, dried over anhydrous MgSO4 and 
concentrated to dryness under diminished pressure, affording a crude residue. The crude 
product was purified by flash silica gel column chromatography using 1:1 ethyl acetate–
hexanes for elution to obtain 4.19 as colorless oil: yield 10 mg (27% over two steps); Rf 
0.45 (1:1 ethyl acetate–hexanes); 1H NMR (CDCl3) δ 1.48-1.53 (m, 1H), 1.73-1.79 (m, 
2H), 1.87-1.93 (m, 1H), 2.01-2.11 (m, 2H), 2.20-2.33 (m, 2H), 2.31-2.35 (m, 2H), 2.62 
(q, 1H, J = 8.0 Hz), 4.31 (quint, 1H, J = 8.0 Hz), 4.62-4.78 (m, 2H), 4.97-5.06 (m, 2H) 
and 5.77-5.86 (m, 2H); 13C NMR (CDCl3) δ 22.9, 28.5, 29.5, 32.5, 35.5, 48.7, 50.2, 55.1, 
114.2, 115.6, 136.9, 172.4 and 173.3; mass spectrum (APCI), m/z 250.1312 (M + H)+ 
(C13H18N2O3 requires m/z 250.1318). 
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(1S, 2S)-2-(Pent-4-enamido)cyclopentanecarboxyl pdCpA (4.20). To a 1.5-mL 
eppendorf tube containing 5.00 mg (3.66 μmol) of the tris(tetrabutylammonium) salt of 
pdCpA was added 4.50 mg (18.0 μmol) of 4.19 dissolved in 100 μL of 9:1 DMF–Et3N. 
After 3 h of sonication, the reaction mixture was purified by C18 reversed phase HPLC 
(250 x 10 mm) using a gradient of 1%→65% acetonitrile in 50 mM ammonium acetate, 
pH 4.5, over a period of 45 min. The fraction eluting at 13.5 min was collected, combined 
and lyophilized to afford 4.20 as a colorless solid: yield 3.0 mg (100%); mass spectrum 
(ESI), m/z 828.2124 (M – H)- (C30H40N9O15P2 requires m/z 828.2119). 
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